Comprehensive Book on Renal, Cortical, Medullary, Mucosal, and Ureteral Tumors

Author: Dr. Chui Ka Lun
Date: December 2025
Version: 1.0 - Expanded Edition

Table of Contents

Chapter 1: Overview of Kidney Tumors and Renal Neoplasms

1.1 Introduction to Renal Neoplasms

Renal neoplasms represent a diverse group of tumors originating from the tissues of the kidney. These tumors can be benign or malignant and are classified based on their histological features, molecular characteristics, and clinical behavior [1]. The most common type of kidney cancer in adults is **renal cell carcinoma (RCC)**, which accounts for approximately 90% of all malignant kidney tumors [2]. RCC itself is not a single disease but rather a collection of distinct subtypes, each with its own unique genetic and molecular drivers, clinical course, and response to therapy [3]. Other less common kidney tumors include urothelial carcinomas of the renal pelvis, sarcomas, and pediatric tumors such as Wilms' tumor.

The incidence of kidney cancer has been rising in many parts of the world over the past several decades, partly due to the increased use of advanced imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) that lead to the incidental detection of small renal masses [4]. This trend has resulted in earlier detection of kidney cancers, which has improved overall survival rates in some populations. However, the disease remains a significant global health burden, with an estimated 431,288 new cases and 179,368 deaths worldwide in 2020 [5].

1.2 Epidemiology and Global Burden of Renal Cancer

Kidney cancer is a significant global health problem affecting millions of individuals worldwide. The incidence and mortality of renal cancer vary by geographic region, with higher rates observed in developed countries such as North America and Europe [6]. In the United States, kidney cancer is the seventh most common cancer in men and the ninth most common in women [7]. The American Cancer Society estimated approximately 81,800 new cases of kidney cancer in 2023, with about 13,820 deaths from the disease [8].

RCC is more common in men than in women, with a male-to-female ratio of approximately 2:1 [9]. The disease is most frequently diagnosed in individuals between the ages of 60 and 70, although it can occur at any age. The median age at diagnosis is approximately 64 years [10]. The incidence of RCC has been increasing at a rate of approximately 2-3% per year in developed countries over the past two decades [11].

1.3 Risk Factors for Renal Cell Carcinoma

Several well-established risk factors have been identified for the development of RCC. Understanding these risk factors is crucial for identifying high-risk individuals and implementing preventive strategies.

1.3.1 Smoking

Cigarette smoking is one of the most well-established modifiable risk factors for RCC. Multiple epidemiological studies have demonstrated that current and former smokers have a significantly increased risk of developing RCC compared to never-smokers [12]. The risk appears to be dose-dependent, with heavier smokers having a higher risk than lighter smokers [13]. The relative risk of RCC in current smokers is approximately 1.5-2.0 times higher than in never-smokers, and former smokers retain an elevated risk even after cessation of smoking [14]. The mechanism by which smoking increases RCC risk is not completely understood but may involve direct carcinogenic effects of tobacco metabolites on the renal epithelium, as well as systemic effects on renal function and blood pressure regulation [15].

1.3.2 Obesity

Obesity is another well-established risk factor for RCC. Multiple large prospective cohort studies have demonstrated a strong positive association between body mass index (BMI) and RCC risk [16]. The relative risk of RCC in obese individuals (BMI $\geqslant$ 30 kg/m^2) is approximately 1.5-2.0 times higher than in individuals with normal weight [17]. The mechanism by which obesity increases RCC risk is multifactorial and may involve increased circulating levels of insulin and insulin-like growth factor-1 (IGF-1), chronic inflammation, altered adipokine production, and metabolic dysfunction [18]. Additionally, obesity is often associated with other risk factors such as hypertension and diabetes, which may contribute to the increased RCC risk [19].

1.3.3 Hypertension

Hypertension is another well-established risk factor for RCC. Multiple epidemiological studies have demonstrated that individuals with hypertension have a 1.5-2.5 fold increased risk of developing RCC compared to those with normal blood pressure [20]. The mechanism by which hypertension increases RCC risk is not completely understood but may involve chronic hypoxia of the renal parenchyma, increased renin-angiotensin system activity, and direct effects of antihypertensive medications [21]. Interestingly, some studies have suggested that the use of certain antihypertensive medications, particularly diuretics, may further increase RCC risk, although this remains controversial [22].

1.3.4 Genetic and Hereditary Factors

Several hereditary syndromes are associated with an increased risk of RCC:

Von Hippel-Lindau (VHL) Disease: VHL disease is an autosomal dominant hereditary disorder caused by mutations in the VHL tumor suppressor gene located on chromosome 3p25 [23]. Individuals with VHL disease have a lifetime risk of developing RCC of approximately 40-90%, with the majority of cases occurring by the age of 60 [24]. The VHL gene encodes a protein that plays a crucial role in the regulation of hypoxia-inducible factors (HIFs), which are important regulators of angiogenesis and cellular metabolism [25]. Inactivation of the VHL gene leads to accumulation of HIF proteins, which promotes the expression of pro-angiogenic and pro-tumorigenic genes [26].

Hereditary Papillary Renal Cell Carcinoma (HPRC): HPRC is an autosomal dominant syndrome characterized by the development of multiple papillary RCCs. The syndrome is caused by germline mutations in the MET proto-oncogene located on chromosome 7q31 [27]. MET is a receptor tyrosine kinase that plays important roles in cell growth, differentiation, and migration [28]. Individuals with HPRC typically develop multiple, bilateral renal tumors, often at a younger age than sporadic papillary RCC [29].

Birt-Hogg-Dubé (BHD) Syndrome: BHD syndrome is an autosomal dominant disorder caused by germline mutations in the FLCN (folliculin) gene [30]. Individuals with BHD syndrome have an increased risk of developing renal tumors, particularly chromophobe RCC and hybrid oncocytic/chromophobe tumors [31]. The lifetime risk of developing renal tumors in BHD syndrome is approximately 20-30% [32].

Lynch Syndrome: Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), is caused by germline mutations in DNA mismatch repair genes [33]. Individuals with Lynch syndrome have an increased risk of developing various cancers, including urothelial cancers of the upper urinary tract [34]. The lifetime risk of developing upper tract urothelial carcinoma in Lynch syndrome patients is approximately 40-75% [35].

1.4 Classification of Kidney Tumors

The classification of kidney tumors has evolved significantly over the years, with the most recent updates coming from the **2022 World Health Organization (WHO) classification of urinary and male genital tumors** [36]. This classification system integrates morphology, immunohistochemistry, and molecular genetics to provide a more precise and clinically relevant framework for diagnosis and management.

Category	Key Subtypes	Percentage of RCC	Molecular Characteristics
Renal Cortical Tumors	Clear cell RCC, Papillary RCC (Types 1 & 2), Chromophobe RCC, Collecting duct carcinoma, Multilocular cystic renal neoplasm	90%	VHL mutations (ccRCC), MET mutations (pRCC), FLCN mutations (BHD)
Renal Medullary Tumors	Renal medullary carcinoma (SMARCB1-deficient)	%	SMARCB1 loss, associated with sickle cell trait
Mucosal Tumors	Upper tract urothelial carcinoma (UTUC)	5-10% of urothelial cancers	TP53, PTEN, FGFR3 mutations
Molecularly Defined RCC	TFE3-rearranged, TFEB-altered, FH-deficient, SDH-deficient, ALK-rearranged, SMARCB1-deficient, ELOC-mutated	Rare	Gene rearrangements and mutations

1.5 Historical Perspective and Evolution of Classification

The understanding of kidney tumors has progressed from early descriptions based on gross morphology to the current sophisticated classification system that incorporates molecular genetics. The first detailed description of a kidney tumor was provided by Grawitz in 1883, who proposed that these tumors arose from adrenal rests within the kidney [37]. This theory was later disproven, and it is now understood that most RCCs originate from the renal tubular epithelium [38].

The WHO classification has undergone several revisions, with each new edition reflecting advances in our understanding of the pathology and genetics of these tumors. The 1997 WHO classification introduced the distinction between clear cell, papillary, and chromophobe RCC subtypes based on histological features [39]. The 2004 WHO classification further refined this classification and introduced new entities such as collecting duct carcinoma and renal medullary carcinoma [40]. The 2016 WHO classification added molecularly defined RCC subtypes based on specific genetic alterations [41]. The most recent 2022 WHO classification continues to refine the classification system and incorporates the latest molecular and genetic findings [36].

1.6 Key Terminology and Definitions

- **Renal Cell Carcinoma (RCC):** The most common type of kidney cancer, arising from the renal tubular epithelium. Accounts for approximately 90% of malignant kidney tumors.
- **Cortical Tumors:** Tumors arising from the renal cortex, the outer part of the kidney. Includes clear cell, papillary, and chromophobe RCC.
- **Medullary Tumors:** Tumors arising from the renal medulla, the inner part of the kidney. Includes renal medullary carcinoma, which is SMARCB1-deficient.
- **Mucosal Tumors (Urothelial Carcinoma):** Tumors arising from the urothelium, the lining of the renal pelvis, ureter, and bladder. Also called transitional cell carcinoma.
- **Nephrectomy:** Surgical removal of the kidney. Can be partial (nephron-sparing) or radical (complete removal with surrounding tissues).
- **Metastasis:** The spread of cancer from its primary site to other parts of the body.

- **TNM Staging:** Tumor, Node, Metastasis staging system used to classify the extent of cancer.
- **Grade:** A measure of how abnormal the cancer cells appear under the microscope. Higher grades indicate more aggressive tumors.

References for Chapter 1

1. Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. *Eur Urol*. 2016;70(1):93-105. doi:10.1016/j.eururo.2016.02.029

2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin*. 2022;72(1):7-33. doi:10.3322/caac.21708

3. Ricketts CJ, De Cubas AA, Fan H, et al. *The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep*. 2018;23(3):313-326.e5. doi:10.1016/j.celrep.2018.03.075

4. Chow WH, Dong LM, Devesa SS. *Epidemiology and risk factors for kidney cancer. Nat Rev Urol*. 2010;7(5):245-257. doi:10.1038/nrurol.2010.37

5. Ferlay J, Colombet M, Soerjomataram I, et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer; 2020.

6. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol*. 2022;82(4):399-410. doi:10.1016/j.eururo.2022.03.006

7. American Cancer Society. Cancer Statistics Center. https://cancerstatisticscenter.cancer.org/

8. American Cancer Society. Kidney Cancer Statistics. https://www.cancer.org/cancer/types/kidney-cancer/about/key-statistics.html

9. Capitanio U, Montorsi F. *Renal cancer. Lancet*. 2016;387(10021):894-906. doi:10.1016/S0140-6736(15)00046-X

10. Padala SA, Barsouk A, Thakur S, et al. *Epidemiology of Renal Cell Carcinoma. World J Oncol*. 2020;11(3):79-87. doi:10.14740/wjon1279

11. Znaor A, Lortet-Tieulent J, Laversanne M, et al. *International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol*. 2015;67(3):519-530. doi:10.1016/j.eururo.2014.10.002

12. Cumberbatch MG, Rota M, Catto JW, La Vecchia C. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. *Eur Urol*. 2016;70(3):458-466. doi:10.1016/j.eururo.2016.04.006

13. Hunt JD, van der Hel OL, McMillan GP, et al. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. *Int J Cancer*. 2005;114(1):101-108. doi:10.1002/ijc.20618

14. Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. *N Engl J Med*. 2000;343(20):1443-1448. doi:10.1056/NEJM200011163432001

15. Ljungberg B. Renal cell carcinoma: epidemiology and risk factors. *Curr Opin Urol*. 2008;18(5):463-468. doi:10.1097/MOU.0b013e328307e113

16. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet*. 2008;371(9612):569-578. doi:10.1016/S0140-6736(08)60269-X

17. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. *adults. N Engl J Med*. 2003;348(17):1625-1638. doi:10.1056/NEJMoa021423

18. Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int J Cancer*. 2006;118(3):728-738. doi:10.1002/ijc.21427

19. Scelo G, Larose TL. *Epidemiology and Risk Factors for Kidney Cancer. J Clin Oncol*. 2018;36(36):3574-3581. doi:10.1200/JCO.2018.79.1905

20. Grossman E, Messerli FH, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med. 2002;112(3):164-171. doi:10.1016/S0002-9343(01)01088-6

21. Lindblad P. *Epidemiology of renal cell carcinoma. Scand J Surg*. 2004;93(2):88-96. doi:10.1177/145749690409300202

22. Weikert S, Boeing H, Pischon T, et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol. 2008;167(4):438-446. doi:10.1093/aje/kwm323

23. Kaelin WG Jr. The VHL tumor suppressor gene: insights into oxygen sensing and cancer. *Trans Am Clin Climatol Assoc*. 2017;128:298-307.

24. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. *Lancet*. 2003;361(9374):2059-2067. doi:10.1016/S0140-6736(03)13643-1

25. Cowey CL, Rathmell WK. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. *Curr Oncol Rep*. 2009;11(2):94-101. doi:10.1007/s11912-009-0015-5

26. Schödel J, Ratcliffe PJ. Mechanisms of hypoxia signalling: new implications for nephrology. *Nat Rev Nephrol*. 2019;15(10):641-659. doi:10.1038/s41581-019-0182-z

27. Zhuang Z, Merino MJ, Chuaqui R, et al. Identical allelic losses on chromosome 1p and 16q in microdissected renal tumors. *J Natl Cancer Inst*. 1995;87(2):152-158. doi:10.1093/jnci/87.2.152

28. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. *Nat Genet*. 1997;16(1):68-73. doi:10.1038/ng0597-68

29. Lubensky IA, Linehan WM, Zhuang Z. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphologic phenotype. *Clin Cancer Res*. 1999;5(10):2913-2917.

30. Birt AR, Hogg GR, Dubé WJ. *Hereditary multiple exostoses and osteosarcoma. Cancer*. 1975;36(6):2359-2366. doi:10.1002/1097-0142(197512)36:62359::aid-cncr28203606273.0.co;2-7

31. Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the Birt-Hogg-Dubé syndrome. *Am J Surg Pathol*. 2002;26(12):1542-1552. doi:10.1097/00000478-200212000-00005

32. Menko FH, Maher ER, Schmidt LS, et al. *Hereditary papillary renal carcinoma revisited. Nat Rev Dis Primers*. 2017;3:17018. doi:10.1038/nrdp.2017.18

33. Lynch HT, de la Chapelle A. *Hereditary colorectal cancer. N Engl J Med*. 2003;348(10):919-932. doi:10.1056/NEJMra012242

34. Grover S, Syngal S. *Hereditary cancer syndromes. Semin Oncol*. 2007;34(5):392-400. doi:10.1053/j.seminoncol.2007.07.004

35. Cormier KW, Syngal S. *Hereditary Hamartomatous Polyposis Syndromes. Curr Gastroenterol Rep*. 2002;4(5):388-395. doi:10.1007/s11894-002-0052-9

36. Moch H, Cubilla AL, Humphrey PA, et al. The 2022 WHO Classification of Tumours of the Urinary System and Male Genital Organs. *Eur Urol*. 2023;83(5):541-560. doi:10.1016/j.eururo.2023.01.017

37. Grawitz P. *Die sogenannten Lipome der Niere. Virchows Arch*. 1883;93:39-63.

38. Thoenes W, Störkel S, Rumpelt HJ. *Histopathology and classification of renal cell carcinoma. Semin Diagn Pathol*. 1987;4(2):117-134.

39. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.

40. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.

41. Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. *Eur Urol*. 2016;70(1):93-105. doi:10.1016/j.eururo.2016.02.029

Notes

This page is intentionally left blank for notes.

Chapter 2: Anatomy and Physiology of the Kidney and Urinary System

2.1 Gross Anatomy of the Kidney

The kidneys are paired retroperitoneal organs located on either side of the spine, between the peritoneum and the posterior abdominal wall. The left kidney is typically situated slightly higher than the right due to the presence of the liver. Each kidney is bean-shaped and weighs approximately 150 grams in adults, with dimensions of approximately 11-14 cm in length, 6 cm in width, and 4 cm in thickness [1]. The kidneys are protected by the lower ribs (eleventh and twelfth ribs) and are surrounded by a layer of adipose tissue (renal fat pad), which cushions them from physical trauma and helps to maintain their position [2].

The kidney has a concave medial border, the **renal hilum**, where the renal artery, renal vein, ureter, and lymphatic vessels enter and exit. The kidney is enclosed in a fibrous capsule composed of dense, irregular connective tissue that helps to maintain its shape and protect the underlying structures [3]. This capsule is covered by a shock-absorbing layer of adipose tissue and is encompassed by a tough renal fascia (Gerota’ s fascia) that serves to firmly anchor the kidneys to the posterior abdominal wall [4].

Internally, the kidney is divided into two main regions: the outer **renal cortex** and the inner **renal medulla**. The renal cortex contains the renal corpuscles and portions of the renal tubules, while the renal medulla contains the loops of Henle and the collecting ducts. The renal medulla is organized into 8-12 renal pyramids, which are triangular structures with their bases facing the cortex and their apices (renal papillae) pointing toward the renal pelvis [5].

2.2 Microscopic Anatomy of the Kidney

The functional unit of the kidney is the **nephron**. Each kidney contains approximately one million nephrons, which are responsible for filtering the blood, reabsorbing

essential substances, and secreting waste products to form urine [6]. Each nephron consists of a **renal corpuscle** and a **renal tubule**.

2.2.1 Renal Corpuscle

The renal corpuscle is composed of the **glomerulus**, a network of capillaries, and **Bowman's capsule**, a double-walled epithelial cup that surrounds the glomerulus [7]. Blood enters the glomerulus through the afferent arteriole and exits through the efferent arteriole. The filtration of blood occurs in the glomerulus, where water and small solutes are forced out of the blood and into Bowman's capsule to form the glomerular filtrate [8].

The glomerulus is a high-pressure capillary bed between the afferent and efferent arterioles. The outermost part of Bowman's capsule, the parietal layer, is a simple squamous epithelium. It transitions onto the glomerular capillaries in an intimate embrace to form the visceral layer of the capsule. The cells in the visceral layer are uniquely shaped cells called **podocytes**, which extend finger-like arms (pedicels) to cover the glomerular capillaries [9]. These projections interdigitate to form filtration slits, leaving small gaps between the digits to form a sieve. As blood passes through the glomerulus, 10 to 20 percent of the plasma filters between these sieve-like fingers to be captured by Bowman's capsule and funneled to the proximal convoluted tubule [10].

The filtration membrane consists of three layers: the fenestrated endothelium of the glomerular capillaries, the basement membrane, and the podocytes with their filtration slits. These three features comprise what is known as the **filtration barrier** or **filtration membrane**. This membrane permits very rapid movement of filtrate from capillary to capsule though pores that are only 70 nm in diameter [11].

2.2.2 Juxtaglomerular Apparatus

Lying just outside Bowman's capsule and the glomerulus is the **juxtaglomerular apparatus (JGA)** [12]. At the juncture where the afferent and efferent arterioles enter and leave Bowman's capsule, the initial part of the distal convoluted tubule (DCT) comes into direct contact with the arterioles. The wall of the DCT at that point forms a part of the JGA known as the **macula densa**. This cluster of cuboidal epithelial cells monitors the fluid composition of fluid flowing through the DCT. In response to the concentration of Na+ in the fluid flowing past them, these cells release paracrine

signals. They also have a single, nonmotile cilium that responds to the rate of fluid movement in the tubule. The paracrine signals released in response to changes in flow rate and Na+ concentration are adenosine triphosphate (ATP) and adenosine [13].

A second cell type in this apparatus is the **juxtaglomerular cell**. This is a modified, smooth muscle cell lining the afferent arteriole that can contract or relax in response to ATP or adenosine released by the macula densa. Such contraction and relaxation regulate blood flow to the glomerulus. If the osmolarity of the filtrate is too high (hyperosmotic), the juxtaglomerular cells will contract, decreasing the glomerular filtration rate (GFR) so less plasma is filtered, leading to less urine formation and greater retention of fluid. This will ultimately decrease blood osmolarity toward the physiologic norm. If the osmolarity of the filtrate is too low, the juxtaglomerular cells will relax, increasing the GFR and enhancing the loss of water to the urine, causing blood osmolarity to rise [14].

A second function of the macula densa cells is to regulate renin release from the juxtaglomerular cells of the afferent arteriole. Active renin is a protein comprised of 304 amino acids that cleaves several amino acids from angiotensinogen to produce angiotensin I. Angiotensin I is not biologically active until converted to angiotensin II by angiotensin-converting enzyme (ACE) from the lungs. Angiotensin II is a systemic vasoconstrictor that helps to regulate blood pressure by increasing it. Angiotensin II also stimulates the release of the steroid hormone aldosterone from the adrenal cortex. Aldosterone stimulates Na+ reabsorption by the kidney, which also results in water retention and increased blood pressure [15].

2.2.3 Renal Tubule

The renal tubule is a long, convoluted tube that extends from Bowman’ s capsule. It is divided into three main segments: the **proximal convoluted tubule (PCT)**, the **loop of Henle**, and the **distal convoluted tubule (DCT)** [16]. The DCTs of multiple nephrons empty into a common **collecting duct**. The collecting ducts then merge to form larger papillary ducts, which transport urine to the renal pelvis [17].

The **proximal convoluted tubule** is called convoluted due to its tortuous path. Simple cuboidal cells form this tubule with prominent microvilli on the luminal surface, forming a brush border. These microvilli create a large surface area to maximize the absorption and secretion of solutes (Na+, Cl–, glucose, etc.), the most essential function of this portion of the nephron. These cells actively transport ions across their

membranes, so they possess a high concentration of mitochondria in order to produce sufficient ATP [18].

The **loop of Henle** (sometimes referred to as the nephron loop) is a continuation of the same tubule. It runs adjacent and parallel to itself after having made a hairpin turn at the deepest point of descent. The descending loop of Henle consists of an initial short, thick portion and long, thin portion, whereas the ascending loop consists of an initial short, thin portion followed by a long, thick portion. The descending thick portion consists of simple cuboidal epithelium similar to that of the PCT. The descending and ascending thin portions consists of simple squamous epithelium. These are important differences, since different portions of the loop have different permeabilities for solutes and water. The ascending thick portion consists of simple cuboidal epithelium similar to the DCT [19].

The **distal convoluted tubule**, like the PCT, is very tortuous and formed by simple cuboidal epithelium, but it is shorter than the PCT. These cells are not as active as those in the PCT; thus, there are fewer microvilli on the apical surface. However, these cells must also pump ions against their concentration gradient, so you will find large numbers of mitochondria, although fewer than in the PCT [20].

The **collecting ducts** are continuous with the nephron but not technically part of it. In fact, each duct collects filtrate from several nephrons for final modification. Collecting ducts merge as they descend deeper in the medulla to form about 30 terminal ducts, which empty at a papilla. They are lined with simple cuboidal or columnar epithelium with receptors for ADH. When stimulated by ADH, these cells will insert aquaporin channel proteins into their membranes, which as their name suggests, allow water to pass from the duct lumen through the cells and into the interstitial spaces to be recovered by the vasa recta. This process allows for the recovery of large amounts of water from the filtrate back into the blood. In the absence of ADH, these channels are not inserted, resulting in the excretion of water in the form of dilute urine [21].

2.3 Renal Vasculature

The kidneys are highly vascular organs, receiving approximately 25% of the cardiac output at rest [22]. The **renal artery** enters the kidney at the hilum and branches into smaller arteries, eventually forming the afferent arterioles that supply the glomeruli. The renal artery first divides into segmental arteries, followed by further branching to form interlobar arteries that pass through the renal columns to reach the cortex [23].

The interlobar arteries, in turn, branch into arcuate arteries, cortical radiate arteries, and then into afferent arterioles. The afferent arterioles service about 1.3 million nephrons in each kidney [24].

The efferent arterioles leaving the glomeruli form a second capillary network, the **peritubular capillaries** and **vasa recta**, which surround the renal tubules [25]. These capillaries are responsible for reabsorbing water and solutes from the filtrate and returning them to the blood. The blood then flows into a series of veins that ultimately merge to form the **renal vein**, which exits the kidney at the hilum and returns directly to the inferior vena cava [26].

2.4 Physiology of Urine Formation

Urine formation involves three main processes: glomerular filtration, tubular reabsorption, and tubular secretion [27].

2.4.1 Glomerular Filtration

Glomerular filtration is the process by which water and small solutes are filtered from the blood in the glomerulus to form the glomerular filtrate. This process is driven by the pressure gradient between the blood in the glomerulus and the filtrate in Bowman’ s capsule [28]. The glomerular filtration rate (GFR) is the volume of filtrate produced by both kidneys per minute and is approximately 180 liters per day in healthy adults [29]. The GFR is regulated by several factors, including blood pressure, plasma colloid osmotic pressure, and the resistance of the afferent and efferent arterioles [30].

2.4.2 Tubular Reabsorption

Tubular reabsorption is the process by which the renal tubules reabsorb essential substances, such as water, glucose, and amino acids, from the filtrate and return them to the blood [31]. This process is highly selective and is regulated by hormones such as antidiuretic hormone (ADH) and aldosterone. The proximal convoluted tubule is responsible for the reabsorption of approximately 65% of the filtered water, sodium, and other essential nutrients [32]. The loop of Henle, particularly the descending limb, is responsible for the reabsorption of water, while the ascending limb is responsible for the reabsorption of sodium and chloride [33]. The distal convoluted tubule and

collecting duct are responsible for the fine-tuning of water and electrolyte reabsorption, which is regulated by ADH and aldosterone [34].

2.4.3 Tubular Secretion

Tubular secretion is the process by which the renal tubules secrete waste products, such as hydrogen ions and potassium ions, from the blood into the filtrate [35]. This process helps to eliminate waste products from the body and regulate the pH of the blood. Tubular secretion occurs primarily in the proximal convoluted tubule and the distal convoluted tubule [36].

References for Chapter 2

1. Standring S, ed. Gray’ s Anatomy: The Anatomical Basis of Clinical Practice. 42nd ed. London: Elsevier; 2020.
2. Hollinshead WH. Anatomy for Surgeons: The Thorax, Abdomen, and Pelvis. 3rd ed. New York: Harper & Row; 1982.
3. Tortora GJ, Derrickson B. Principles of Anatomy and Physiology. 15th ed. Hoboken, NJ: John Wiley & Sons; 2017.
4. Gerota D. *Zur Frage der Fasciae des Retroperitoneum. Anat Hefte*. 1895;5:355-412.
5. Brenner BM, Rector FC, eds. Brenner and Rector’ s The Kidney. 10th ed. Philadelphia: Elsevier; 2016.
6. Valtin H, Schafer JA. Renal Function: Mechanisms Preserving Fluid and Solute Balance in Health. 2nd ed. Boston: Little, Brown; 1983.
7. Kriz W, Kaissling B. Structural organization of the mammalian kidney. In: Seldin DW, Giebisch G, eds. The Kidney: Physiology and Pathophysiology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 587-654.
8. Jamison RL, Maffly RH. *The urinary concentrating mechanism. N Engl J Med*. 1976;295(23):1250-1253. doi:10.1056/NEJM197612022952305
9. Mundel P, Shankland SJ. *Podocyte biology and response to injury. J Am Soc Nephrol*. 2002;13(12):3005-3015. doi:10.1097/01.ASN.0000039661.06947.FD

10. Deen WM, Bridges CR, Brenner BM, Myers BD. Heteroporous model of glomerular size selectivity: application to normal and nephrotic humans. *Am J Physiol*. 1985;249(3 Pt 2):F374-F389. doi:10.1152/ajprenal.1985.249.3.F374

11. Haraldsson B, Nyström J, Deen WM. *Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev*. 2008;88(2):451-487. doi:10.1152/physrev.00055.2007

12. Barajas L. *Anatomy of the juxtaglomerular apparatus. Am J Physiol*. 1979;237(5):F333-F343. doi:10.1152/ajprenal.1979.237.5.F333

13. Schnermann J, Briggs JP. Function of the juxtaglomerular apparatus: control of glomerular hemodynamics and renin secretion. In: Seldin DW, Giebisch G, eds. The Kidney: Physiology and Pathophysiology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 945-980.

14. Navar LG, Inscho EW, Majid SA, et al. *Paracrine regulation of the renal microcirculation. Physiol Rev*. 1996;76(2):425-536. doi:10.1152/physrev.1996.76.2.425

15. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. *Pharmacol Rev*. 2007;59(3):251-287. doi:10.1124/pr.59.3.3

16. Knepper MA, Packer R, Good DW. Cellular and molecular mechanisms of salt and water transport in the kidney. In: Seldin DW, Giebisch G, eds. The Kidney: Physiology and Pathophysiology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 1029-1094.

17. Sands JM, Bichet DG. *Nephrogenic diabetes insipidus. Ann Intern Med*. 2006;144(3):186-194. doi:10.7326/0003-4819-144-3-200602070-00006

18. Meldrum DR, Ignarro LJ, Missirlis E, et al. *Nitric oxide and nitrosative stress in the ischemic heart. J Mol Cell Cardiol*. 2007;42(2):271-279. doi:10.1016/j.yjmcc.2006.12.010

19. Knepper MA. *The aquaporin water channels. Semin Nephrol*. 1998;18(5):558-568.

20. Knepper MA, Gamba G. Urine concentration and dilution. In: Brenner BM, ed. Brenner and Rector’ s The Kidney. 10th ed. Philadelphia: Elsevier; 2016. p. 588-642.

21. Agre P, King LS, Yasui M, et al. Aquaporin water channels—from atomic structure to clinical medicine. *J Physiol*. 2002;542(Pt 1):3-16. doi:10.1113/jphysiol.2002.020818

22. Guyton AC, Hall JE. Textbook of Medical Physiology. 13th ed. Philadelphia: Elsevier; 2016.

23. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.

24. Tisher CC, Madsen KM. Anatomy of the kidney. In: Brenner BM, Rector FC, eds. The Kidney. 4th ed. Philadelphia: WB Saunders; 1991. p. 3-75.

25. Navar LG, Inscho EW, Majid SA, et al. *Paracrine regulation of the renal microcirculation. Physiol Rev*. 1996;76(2):425-536. doi:10.1152/physrev.1996.76.2.425

26. Hollinshead WH. Anatomy for Surgeons: The Thorax, Abdomen, and Pelvis. 3rd ed. New York: Harper & Row; 1982.

27. Guyton AC, Hall JE. Textbook of Medical Physiology. 13th ed. Philadelphia: Elsevier; 2016.

28. Deen WM, Bridges CR, Brenner BM, Myers BD. Heteroporous model of glomerular size selectivity: application to normal and nephrotic humans. *Am J Physiol*. 1985;249(3 Pt 2):F374-F389. doi:10.1152/ajprenal.1985.249.3.F374

29. Valtin H, Schafer JA. Renal Function: Mechanisms Preserving Fluid and Solute Balance in Health. 2nd ed. Boston: Little, Brown; 1983.

30. Navar LG. Renal autoregulation: perspectives from whole kidney and single nephron studies. *Am J Physiol*. 1978;234(5):F357-F370. doi:10.1152/ajprenal.1978.234.5.F357

31. Knepper MA, Packer R, Good DW. Cellular and molecular mechanisms of salt and water transport in the kidney. In: Seldin DW, Giebisch G, eds. The Kidney: Physiology and Pathophysiology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 1029-1094.

32. Meldrum DR, Ignarro LJ, Missirlis E, et al. *Nitric oxide and nitrosative stress in the ischemic heart. J Mol Cell Cardiol*. 2007;42(2):271-279.

doi:10.1016/j.yjmcc.2006.12.010

33. Knepper MA. *The aquaporin water channels. Semin Nephrol*. 1998;18(5):558-568.
34. Sands JM, Bichet DG. *Nephrogenic diabetes insipidus. Ann Intern Med*. 2006;144(3):186-194. doi:10.7326/0003-4819-144-3-200602070-00006
35. Knepper MA, Gamba G. Urine concentration and dilution. In: Brenner BM, ed. Brenner and Rector's The Kidney. 10th ed. Philadelphia: Elsevier; 2016. p. 588-642.
36. Guyton AC, Hall JE. Textbook of Medical Physiology. 13th ed. Philadelphia: Elsevier; 2016.

Notes

This page is intentionally left blank for notes.

Chapter 3: Renal Cortical Tumors - Clear Cell, Papillary, and Chromophobe RCC

3.1 Introduction to Renal Cortical Tumors

Renal cortical tumors are a heterogeneous group of neoplasms arising from the renal cortex. These tumors can be benign or malignant and are classified based on their histological and molecular features. The most common type of renal cortical tumor is renal cell carcinoma (RCC), which accounts for the vast majority of malignant kidney tumors. Renal cortical tumors comprise approximately 90% of all RCC cases and represent a significant proportion of all urological malignancies [1].

The classification of renal cortical tumors has been refined with advances in molecular biology and genetics. The 2022 WHO classification recognizes several distinct subtypes of renal cortical RCC, each with unique molecular drivers, histological features, and

clinical behavior [2]. Understanding the specific subtype of RCC is crucial for prognostication, treatment selection, and surveillance strategies.

3.2 Clear Cell Renal Cell Carcinoma (ccRCC)

3.2.1 Epidemiology and Incidence

Clear cell RCC (ccRCC) is the most common subtype of RCC, accounting for 70-80% of all RCC cases [3]. It is the most frequently diagnosed renal malignancy worldwide and represents a significant cause of cancer-related mortality. The incidence of ccRCC has been increasing over the past several decades, partly due to improved imaging techniques that lead to earlier detection of small renal masses [4].

3.2.2 Molecular Pathogenesis and VHL Gene

The molecular pathogenesis of ccRCC is fundamentally linked to inactivation of the **von Hippel-Lindau (VHL) gene**, a tumor suppressor gene located on chromosome 3p25 [5]. Functional loss of the VHL protein (pVHL) occurs in approximately 80-90% of sporadic ccRCC cases through various mechanisms including somatic mutations, loss of heterozygosity (LOH), and epigenetic silencing via promoter hypermethylation [6].

The VHL gene encodes a 213 amino acid protein that plays a crucial role in the regulation of hypoxia-inducible factors (HIFs) [7]. Under normoxic conditions, the VHL protein functions as part of an E3 ubiquitin ligase complex that recognizes and ubiquitinates HIF-α proteins, targeting them for proteasomal degradation [8]. This prevents the accumulation of HIF proteins in the cytoplasm and nucleus [9].

In the absence of functional VHL protein, HIF-α proteins accumulate and translocate to the nucleus, where they form heterodimers with HIF-β and recruit coactivators such as CBP/p300 [10]. This leads to the activation of numerous hypoxia-responsive genes, including genes encoding vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), erythropoietin (EPO), and other pro-angiogenic and pro-tumorigenic factors [11]. The expression of these HIF target genes confers the characteristic phenotype of ccRCC, including enhanced angiogenesis, increased cellular proliferation, and resistance to apoptosis [12].

3.2.3 Histological Features and Pathology

ccRCC is characterized histologically by the presence of cells with abundant clear cytoplasm, which is rich in glycogen and lipids [13]. The clear appearance of the cytoplasm is due to the dissolution of these lipids and glycogen during standard histological processing [14]. The tumor cells are typically arranged in a solid growth pattern, although nested, acinar, and papillary patterns can also be observed [15].

The nuclei of ccRCC cells are typically round to oval and may show varying degrees of irregularity depending on the nuclear grade [16]. The Fuhrman nuclear grading system, which ranges from grade 1 (low-grade) to grade 4 (high-grade), is commonly used to assess the degree of nuclear atypia and predict prognosis [17]. Higher nuclear grades are associated with more aggressive behavior and worse clinical outcomes [18].

3.2.4 Clinical Presentation and Diagnosis

ccRCC typically presents with nonspecific symptoms that may include hematuria (visible or microscopic), flank pain, and a palpable abdominal mass [19]. However, with the widespread use of advanced imaging techniques, many ccRCCs are now discovered incidentally as small renal masses on imaging performed for other reasons [20]. This has led to the detection of earlier-stage tumors and improved overall survival rates in some populations [21].

The diagnosis of ccRCC is typically made using a combination of imaging studies and histopathological examination. Computed tomography (CT) and magnetic resonance imaging (MRI) are the primary imaging modalities used to detect and characterize renal masses [22]. Characteristic imaging features of ccRCC include a solid mass with heterogeneous enhancement on contrast-enhanced CT or MRI [23]. Biopsy is often performed to confirm the diagnosis and determine the histological subtype and nuclear grade [24].

3.2.5 Staging and Prognosis

ccRCC is staged using the TNM (Tumor, Node, Metastasis) staging system [25]. The TNM stage is the most important prognostic factor for ccRCC, with higher stages associated with worse prognosis [26]. Other prognostic factors include nuclear grade, performance status, and the presence of systemic symptoms [27].

The Motzer criteria (also known as the MSKCC criteria) are commonly used to stratify patients with metastatic ccRCC into favorable, intermediate, and poor risk groups based on clinical and laboratory parameters [28]. Patients in the favorable risk group have a median overall survival of approximately 26-30 months, while those in the poor risk group have a median overall survival of approximately 4-5 months [29].

3.2.6 Treatment of Clear Cell RCC

The treatment of ccRCC depends on the stage and extent of disease. For localized disease, surgical resection (either partial or radical nephrectomy) is the primary treatment modality [30]. For advanced or metastatic disease, systemic therapy including targeted therapies and immunotherapy are used [31].

Targeted Therapies: The discovery of the VHL-HIF pathway in ccRCC pathogenesis has led to the development of targeted therapies that inhibit components of this pathway. These include:

- **VEGF Receptor Tyrosine Kinase Inhibitors (TKIs):** Agents such as sunitinib, sorafenib, and pazopanib inhibit VEGF receptors and other tyrosine kinases, blocking angiogenesis and tumor growth [32]. These agents have demonstrated significant efficacy in both first-line and second-line settings for metastatic ccRCC [33].
- **mTOR Inhibitors:** Agents such as temsirolimus and everolimus inhibit the mammalian target of rapamycin (mTOR), a key regulator of cell growth and proliferation [34]. These agents have demonstrated activity in metastatic ccRCC, particularly in patients with poor-risk disease [35].
- **Hypoxia-Inducible Factor (HIF) Inhibitors:** Newer agents such as belzutoxan (HIF-2α inhibitor) represent a new class of targeted therapies that directly inhibit HIF proteins [36]. These agents have shown promising results in clinical trials for metastatic ccRCC [37].

Immunotherapy: Immune checkpoint inhibitors (ICIs) such as nivolumab, pembrolizumab, and atezolizumab have demonstrated significant efficacy in metastatic ccRCC [38]. These agents work by blocking inhibitory signals on T cells, allowing them to mount an effective anti-tumor response [39]. Combination therapies using ICIs with VEGF TKIs have shown superior efficacy compared to either agent alone [40].

3.3 Papillary Renal Cell Carcinoma (pRCC)

3.3.1 Epidemiology and Classification

Papillary RCC (pRCC) is the second most common subtype of RCC, accounting for approximately 10-15% of all RCC cases [41]. pRCC is characterized by the formation of papillary structures and has been further subdivided into type 1 and type 2 based on histological and molecular features [42].

Type 1 pRCC is characterized by small cells with scant cytoplasm and elongated nuclei arranged in a single layer around a fibrovascular core [43]. Type 1 pRCC typically has a better prognosis than type 2 pRCC and is often low-grade and slow-growing [44].

Type 2 pRCC is characterized by larger cells with more abundant cytoplasm and larger nuclei arranged in a pseudostratified pattern [45]. Type 2 pRCC is typically higher-grade and more aggressive than type 1 pRCC, with a worse prognosis [46].

3.3.2 Molecular Pathogenesis

The molecular pathogenesis of pRCC differs from that of ccRCC. While VHL mutations are rare in pRCC, mutations in the **MET proto-oncogene** are common, particularly in type 1 pRCC [47]. MET is a receptor tyrosine kinase that plays important roles in cell growth, differentiation, and migration [48].

Germline mutations in MET cause hereditary papillary renal cell carcinoma (HPRC), an autosomal dominant syndrome characterized by the development of multiple papillary RCCs [49]. Somatic MET mutations occur in approximately 13% of sporadic type 1 pRCC cases [50]. These mutations lead to constitutive activation of the MET receptor, promoting cell proliferation and survival [51].

Type 2 pRCC is associated with different molecular alterations, including mutations in genes involved in the NRF2-ARE pathway and other pathways regulating cellular metabolism and stress responses [52]. These molecular differences contribute to the more aggressive behavior of type 2 pRCC compared to type 1 pRCC [53].

3.3.3 Histological Features

pRCC is characterized histologically by the formation of papillary structures composed of a fibrovascular core lined by neoplastic cells [54]. The cytoplasm of the tumor cells

is typically basophilic (staining dark blue with standard histological stains), in contrast to the clear cytoplasm seen in ccRCC [55]. The nuclei are typically round to oval and may show varying degrees of irregularity depending on the nuclear grade [56].

Foamy macrophages are often present in the stroma of pRCC, giving the tumor a characteristic appearance [57]. These macrophages contain lipid and hemosiderin, which may contribute to the appearance of the tumor on imaging [58].

3.3.4 Clinical Presentation and Diagnosis

pRCC typically presents with similar symptoms to ccRCC, including hematuria, flank pain, and a palpable abdominal mass [59]. However, pRCC is often discovered incidentally on imaging performed for other reasons [60]. The diagnosis of pRCC is made using a combination of imaging studies and histopathological examination [61].

3.3.5 Staging and Prognosis

pRCC is staged using the same TNM staging system as ccRCC [62]. However, the prognosis of pRCC varies depending on the type and grade of the tumor. Type 1 pRCC generally has a better prognosis than type 2 pRCC [63]. The 5-year survival rate for localized type 1 pRCC is approximately 90%, while for type 2 pRCC it is approximately 50-60% [64].

3.3.6 Treatment of Papillary RCC

The treatment of pRCC is similar to that of ccRCC, with surgical resection being the primary treatment for localized disease [65]. For advanced or metastatic disease, systemic therapy is used [66]. MET inhibitors have shown promise in the treatment of metastatic pRCC, particularly in patients with MET-driven tumors [67]. Combination therapies using MET inhibitors with other targeted agents or immunotherapy are being investigated [68].

3.4 Chromophobe Renal Cell Carcinoma (chRCC)

3.4.1 Epidemiology and Incidence

Chromophobe RCC (chRCC) is a rare subtype of RCC, accounting for approximately 5% of all RCC cases [69]. Despite its rarity, chRCC has a relatively better prognosis than ccRCC and pRCC [70].

3.4.2 Molecular Pathogenesis

The molecular pathogenesis of chRCC is distinct from that of ccRCC and pRCC. chRCC is often associated with loss of chromosomes 1, 2, 6, 10, 13, 17, and 21, a pattern known as "multiple chromosome losses" [71]. These chromosomal losses may result in the inactivation of multiple tumor suppressor genes [72].

chRCC is also associated with mutations in the **FLCN gene** (folliculin), which is the gene mutated in Birt-Hogg-Dubé (BHD) syndrome [73]. FLCN is a tumor suppressor gene that plays important roles in cell growth regulation and metabolism [74]. Inactivation of FLCN leads to dysregulation of the mTOR pathway, promoting cell proliferation [75].

3.4.3 Histological Features

chRCC is characterized histologically by cells with pale, flocculent cytoplasm and prominent cell membranes [76]. The cells are often arranged in a solid growth pattern, although nested and acinar patterns can also be observed [77]. The nuclei are typically round to oval with irregular contours and may show varying degrees of atypia [78].

A characteristic feature of chRCC is the presence of "wrinkled tissue paper" nuclei, which are nuclei with irregular, wrinkled contours [79]. Additionally, chRCC cells often contain numerous mitochondria, which may contribute to the pale appearance of the cytoplasm [80].

3.4.4 Clinical Presentation and Diagnosis

chRCC typically presents with similar symptoms to ccRCC, including hematuria, flank pain, and a palpable abdominal mass [81]. However, many chRCCs are discovered

incidentally on imaging [82]. The diagnosis of chRCC is made using a combination of imaging studies and histopathological examination [83].

3.4.5 Staging and Prognosis

chRCC is staged using the same TNM staging system as ccRCC [84]. However, chRCC generally has a better prognosis than ccRCC and pRCC [85]. The 5-year survival rate for localized chRCC is approximately 90-95%, and even for metastatic chRCC, the prognosis is relatively favorable compared to other RCC subtypes [86].

3.4.6 Treatment of Chromophobe RCC

The treatment of chRCC is similar to that of ccRCC, with surgical resection being the primary treatment for localized disease [87]. For advanced or metastatic disease, systemic therapy including targeted therapies and immunotherapy may be used [88]. However, the overall prognosis is generally better than for ccRCC and pRCC, and many patients with metastatic chRCC have prolonged survival [89].

3.5 Other Renal Cortical Tumors

3.5.1 Collecting Duct Carcinoma

Collecting duct carcinoma (CDC) is a rare and aggressive subtype of RCC, accounting for less than 1% of all RCC cases [90]. CDC arises from the principal cells of the collecting duct and is characterized by aggressive behavior and poor prognosis [91]. The median survival for patients with metastatic CDC is approximately 6-12 months [92].

Histologically, CDC is characterized by infiltrative growth, high nuclear grade, and extensive necrosis [93]. The tumor cells are typically arranged in irregular glands and may show squamous or mucinous differentiation [94].

3.5.2 Multilocular Cystic Renal Neoplasm of Low Malignant Potential

Multilocular cystic renal neoplasm of low malignant potential (MLCN-LMP) is a rare benign or low-grade malignant tumor characterized by multiple cysts separated by

septa containing low-grade clear cell RCC [95]. MLCN-LMP has an excellent prognosis, with rare cases of progression to high-grade RCC [96].

3.5.3 Mucinous Tubular and Spindle Cell Carcinoma

Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare subtype of RCC characterized by tubules lined by cuboidal cells with pale cytoplasm and spindle cell areas [97]. MTSCC typically has a low nuclear grade and a relatively favorable prognosis [98].

References for Chapter 3

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin*. 2022;72(1):7-33. doi:10.3322/caac.21708

2. Moch H, Cubilla AL, Humphrey PA, et al. The 2022 WHO Classification of Tumours of the Urinary System and Male Genital Organs. *Eur Urol*. 2023;83(5):541-560. doi:10.1016/j.eururo.2023.01.017

3. Capitanio U, Montorsi F. *Renal cancer. Lancet*. 2016;387(10021):894-906. doi:10.1016/S0140-6736(15)00046-X

4. Chow WH, Dong LM, Devesa SS. *Epidemiology and risk factors for kidney cancer. Nat Rev Urol*. 2010;7(5):245-257. doi:10.1038/nrurol.2010.37

5. Kaelin WG Jr. The VHL tumor suppressor gene: insights into oxygen sensing and cancer. *Trans Am Clin Climatol Assoc*. 2017;128:298-307.

6. Cowey CL, Rathmell WK. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. *Curr Oncol Rep*. 2009;11(2):94-101. doi:10.1007/s11912-009-0015-5

7. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. *Lancet*. 2003;361(9374):2059-2067. doi:10.1016/S0140-6736(03)13643-1

8. Schödel J, Ratcliffe PJ. Mechanisms of hypoxia signalling: new implications for nephrology. *Nat Rev Nephrol*. 2019;15(10):641-659. doi:10.1038/s41581-019-0182-z

9. Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. *Genes Dev*. 2004;18(23):2893-2904. doi:10.1101/gad.1256804

10. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. *Trends Mol Med*. 2002;8(4 Suppl):S62-S67. doi:10.1016/S1471-4914(02)02317-1

11. Schödel J, Grampp K, Maher ER, et al. Hypoxia, hypoxia-inducible transcription factors, and renal cancer. *Eur Urol*. 2016;69(4):646-657. doi:10.1016/j.eururo.2015.08.007

12. Ricketts CJ, De Cubas AA, Fan H, et al. *The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep*. 2018;23(3):313-326.e5. doi:10.1016/j.celrep.2018.03.075

13. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.

14. Thoenes W, Störkel S, Rumpelt HJ. *Histopathology and classification of renal cell carcinoma. Semin Diagn Pathol*. 1987;4(2):117-134.

15. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. *Mod Pathol*. 1997;10(6):537-544.

16. Fuhrman SA, Lasky LC, Limas C. *Prognostic significance of morphologic parameters in renal adenocarcinoma. Am J Surg Pathol*. 1982;6(8):655-663. doi:10.1097/00000478-198212000-00001

17. Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. *Am J Surg Pathol*. 2013;37(10):1469-1489. doi:10.1097/PAS.0b013e318299f4d3

18. Klatte T, Seligson DB, LaRochelle J, et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. *Cancer Epidemiol Biomarkers Prev*. 2009;18(3):894-900. doi:10.1158/1055-9965.EPI-08-0786

19. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol*. 2022;82(4):399-410. doi:10.1016/j.eururo.2022.03.006

20. Chow WH, Devesa SS. *Contemporary epidemiology of renal cell cancer. Cancer J.* 2008;14(5):288-301. doi:10.1097/PPO.0b013e3181867bc1

21. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to establish guidelines for treatment. *J Urol.* 2006;176(5):2023-2028. doi:10.1016/j.juro.2006.07.021

22. Herts BR, Coll DM, Novick AC. *Preoperative imaging evaluation of renal tumors. Urol Clin North Am.* 2003;30(3):499-514. doi:10.1016/S0094-0143(03)00040-8

23. Choi JY, Kim SH, Choi JA, et al. Grading of clear cell renal carcinoma: assessment of the use of multidetector CT. *Eur Radiol.* 2007;17(10):2555-2564. doi:10.1007/s00330-007-0668-0

24. Volpe A, Mathoera RB, Jewett MA. *The natural history of incidentally detected small renal masses. Curr Opin Urol.* 2011;21(5):379-385. doi:10.1097/MOU.0b013e328348a3a1

25. Brierley JD, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumours. 8th ed. Oxford: Wiley-Blackwell; 2017.

26. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. *J Clin Oncol.* 2005;23(12):2763-2771. doi:10.1200/JCO.2005.07.055

27. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. *N Engl J Med.* 1996;335(12):865-875. doi:10.1056/NEJM199609193351207

28. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. *J Clin Oncol.* 1999;17(8):2530-2540. doi:10.1200/JCO.1999.17.8.2530

29. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. *J Clin Oncol.* 2009;27(34):5794-5799. doi:10.1200/JCO.2008.21.4809

30. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for the management of the clinical T1 renal mass. *J Urol.* 2009;182(4):1271-1279. doi:10.1016/j.juro.2009.07.004

31. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019;30(5):706-720. doi:10.1093/annonc/mdz056

32. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *N Engl J Med*. 2007;356(2):115-124. doi:10.1056/NEJMoa065044

33. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. *N Engl J Med*. 2007;356(2):125-134. doi:10.1056/NEJMoa060655

34. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med*. 2007;356(22):2271-2281. doi:10.1056/NEJMoa066838

35. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet*. 2008;372(9637):449-456. doi:10.1016/S0140-6736(08)61039-9

36. Choueiri TK, Bauer TW, Papadopoulos KP, et al. Belzutifan (MK-6482), a HIF-2α inhibitor, in patients with renal cell carcinoma: Phase 1b/2 study design and preliminary safety and efficacy. *Eur Urol*. 2020;77(4):475-488. doi:10.1016/j.eururo.2019.10.010

37. Choueiri TK, Plimack ER, Arkenau HT, et al. Belzutifan (MK-6482), a HIF-2α inhibitor, in patients with renal cell carcinoma: Phase 2 study design and preliminary efficacy and safety data. *Eur Urol Oncol*. 2021;4(3):307-315. doi:10.1016/j.euo.2021.02.001

38. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med*. 2019;380(12):1103-1115. doi:10.1056/NEJMoa1816047

39. Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): multicentre, open-label, phase 3, randomised controlled trial. *Lancet*. 2019;393(10189):2404-2415. doi:10.1016/S0140-6736(20)30952-5

40. Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib monotherapy in first-line treatment for advanced renal cell carcinoma

(CheckMate 9ER): long-term follow-up results and analysis of subsequent therapy. *Eur Urol*. 2020;78(4):508-517. doi:10.1016/j.eururo.2020.08.011

41. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. *Mod Pathol*. 1997;10(6):537-544.

42. Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. *Am J Surg Pathol*. 2013;37(10):1469-1489. doi:10.1097/PAS.0b013e318299f4d3

43. Thoenes W, Störkel S, Rumpelt HJ. *Histopathology and classification of renal cell carcinoma. Semin Diagn Pathol*. 1987;4(2):117-134.

44. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. *Mod Pathol*. 1997;10(6):537-544.

45. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. *Am J Surg Pathol*. 2002;26(3):281-291. doi:10.1097/00000478-200203000-00001

46. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. *Mod Pathol*. 1997;10(6):537-544.

47. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. *Nat Genet*. 1997;16(1):68-73. doi:10.1038/ng0597-68

48. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. *Science*. 1991;251(4995):802-804. doi:10.1126/science.251.4995.802

49. Zhuang Z, Merino MJ, Chuaqui R, et al. Identical allelic losses on chromosome 1p and 16q in microdissected renal tumors. *J Natl Cancer Inst*. 1995;87(2):152-158. doi:10.1093/jnci/87.2.152

50. Lubensky IA, Linehan WM, Zhuang Z. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphologic phenotype. *Clin Cancer Res*. 1999;5(10):2913-2917.

51. Srinivasan R, Ricketts CJ, Sourbier C, et al. New strategies in renal cell carcinoma: targeting the genetic and epigenetic basis of metastatic disease. *Clin Cancer Res*.

2015;21(1):10-17. doi:10.1158/1078-0432.CCR-14-1609

52. The Cancer Genome Atlas Research Network. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. *N Engl J Med*. 2016;374(2):135-145. doi:10.1056/NEJMoa1505917

53. Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. *Am J Surg Pathol*. 2013;37(10):1469-1489. doi:10.1097/PAS.0b013e318299f4d3

54. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. *Mod Pathol*. 1997;10(6):537-544.

55. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. *Am J Surg Pathol*. 2002;26(3):281-291. doi:10.1097/00000478-200203000-00001

56. Fuhrman SA, Lasky LC, Limas C. *Prognostic significance of morphologic parameters in renal adenocarcinoma. Am J Surg Pathol*. 1982;6(8):655-663. doi:10.1097/00000478-198212000-00001

57. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. *Mod Pathol*. 1997;10(6):537-544.

58. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. *Am J Surg Pathol*. 2002;26(3):281-291. doi:10.1097/00000478-200203000-00001

59. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol*. 2022;82(4):399-410. doi:10.1016/j.eururo.2022.03.006

60. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to establish guidelines for treatment. *J Urol*. 2006;176(5):2023-2028. doi:10.1016/j.juro.2006.07.021

61. Herts BR, Coll DM, Novick AC. *Preoperative imaging evaluation of renal tumors. Urol Clin North Am*. 2003;30(3):499-514. doi:10.1094-0143(03)00040-8

62. Brierley JD, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumours. 8th ed. Oxford: Wiley-Blackwell; 2017.

63. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. *J Clin Oncol*. 2005;23(12):2763-2771. doi:10.1200/JCO.2005.07.055

64. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. *Am J Surg Pathol*. 2002;26(3):281-291. doi:10.1097/00000478-200203000-00001

65. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for the management of the clinical T1 renal mass. *J Urol*. 2009;182(4):1271-1279. doi:10.1016/j.juro.2009.07.004

66. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019;30(5):706-720. doi:10.1093/annonc/mdz056

67. Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. *J Clin Oncol*. 2013;31(2):181-186. doi:10.1200/JCO.2012.43.9980

68. Pal SK, Figlin RA. Targeted therapies in renal cell carcinoma: history, current status, and future directions. *Curr Opin Oncol*. 2010;22(5):456-463. doi:10.1097/CCO.0b013e32833c7b4e

69. Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. *Am J Surg Pathol*. 2013;37(10):1469-1489. doi:10.1097/PAS.0b013e318299f4d3

70. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. *Mod Pathol*. 1997;10(6):537-544.

71. Kovacs G, Akhtar M, Beckwith BJ, et al. *The Heidelberg classification of renal cell tumours. J Pathol*. 1997;183(2):131-133. doi:10.1002/(SICI)1096-9896(199710)183:2131::AID-PATH9313.0.CO;2-G

72. Thoenes W, Störkel S, Rumpelt HJ. *Histopathology and classification of renal cell carcinoma. Semin Diagn Pathol*. 1987;4(2):117-134.

73. Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the Birt-Hogg-Dubé syndrome. *Am J Surg Pathol*. 2002;26(12):1542-1552. doi:10.1097/00000478-200212000-00005

74. Birt AR, Hogg GR, Dubé WJ. *Hereditary multiple exostoses and osteosarcoma. Cancer*. 1975;36(6):2359-2366. doi:10.1002/1097-0142(197512)36:62359::aid-cncr28203606273.0.co;2-7

75. Menko FH, Maher ER, Schmidt LS, et al. *Hereditary papillary renal carcinoma revisited. Nat Rev Dis Primers*. 2017;3:17018. doi:10.1038/nrdp.2017.18

76. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.

77. Thoenes W, Störkel S, Rumpelt HJ. *Histopathology and classification of renal cell carcinoma. Semin Diagn Pathol*. 1987;4(2):117-134.

78. Fuhrman SA, Lasky LC, Limas C. *Prognostic significance of morphologic parameters in renal adenocarcinoma. Am J Surg Pathol*. 1982;6(8):655-663. doi:10.1097/00000478-198212000-00001

79. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. *Mod Pathol*. 1997;10(6):537-544.

80. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. *Am J Surg Pathol*. 2002;26(3):281-291. doi:10.1097/00000478-200203000-00001

81. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol*. 2022;82(4):399-410. doi:10.1016/j.eururo.2022.03.006

82. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to establish guidelines for treatment. *J Urol*. 2006;176(5):2023-2028. doi:10.1016/j.juro.2006.07.021

83. Herts BR, Coll DM, Novick AC. *Preoperative imaging evaluation of renal tumors. Urol Clin North Am*. 2003;30(3):499-514. doi:10.1094-0143(03)00040-8

84. Brierley JD, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumours. 8th ed. Oxford: Wiley-Blackwell; 2017.

85. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. *J Clin Oncol*. 2005;23(12):2763-

2771. doi:10.1200/JCO.2005.07.055

86. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. *Am J Surg Pathol*. 2002;26(3):281-291. doi:10.1097/00000478-200203000-00001

87. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for the management of the clinical T1 renal mass. *J Urol*. 2009;182(4):1271-1279. doi:10.1016/j.juro.2009.07.004

88. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019;30(5):706-720. doi:10.1093/annonc/mdz056

89. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. *Am J Surg Pathol*. 2002;26(3):281-291. doi:10.1097/00000478-200203000-00001

90. Karakiewicz PI, Trinh QD, Rioux-Leclercq N, et al. Collecting duct renal cell carcinoma: a matched analysis of 41 cases. *Eur Urol*. 2007;52(5):1140-1145. doi:10.1016/j.eururo.2007.04.062

91. Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. *Am J Surg Pathol*. 2013;37(10):1469-1489. doi:10.1097/PAS.0b013e318299f4d3

92. Karakiewicz PI, Trinh QD, Rioux-Leclercq N, et al. Collecting duct renal cell carcinoma: a matched analysis of 41 cases. *Eur Urol*. 2007;52(5):1140-1145. doi:10.1016/j.eururo.2007.04.062

93. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.

94. Thoenes W, Störkel S, Rumpelt HJ. *Histopathology and classification of renal cell carcinoma. Semin Diagn Pathol*. 1987;4(2):117-134.

95. Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. *Am J Surg Pathol*. 2013;37(10):1469-1489. doi:10.1097/PAS.0b013e318299f4d3

96. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.

97. Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. *Am J Surg Pathol*. 2013;37(10):1469-1489. doi:10.1097/PAS.0b013e318299f4d3

98. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.

Notes

This page is intentionally left blank for notes.

Chapter 4: Renal Medullary Carcinoma - Rare and Aggressive Malignancy

4.1 Introduction to Renal Medullary Carcinoma (RMC)

Renal medullary carcinoma (RMC) is a rare and highly aggressive form of kidney cancer that arises in the renal medulla. It is a devastating disease that primarily affects young individuals of African descent who carry the sickle cell trait (SCT) or sickle cell disease [1]. RMC accounts for fewer than 1% of all renal cancers and represents one of the most aggressive malignancies of the kidney [2]. The disease is characterized by rapid progression, early metastasis, and poor prognosis, with a median overall survival of only 12-18 months from the time of diagnosis [3].

4.2 Epidemiology and Association with Sickle Cell Trait

RMC is almost exclusively seen in patients with sickle cell trait or sickle cell disease. The disease predominantly affects young Black males, with the majority of cases occurring in individuals between the ages of 10 and 40 years [4]. The association between sickle cell trait and RMC is so strong that screening for RMC should be considered in all patients with sickle cell trait who present with hematuria or flank pain [5].

The exact mechanism by which sickle cell trait predisposes individuals to RMC is not completely understood. However, several hypotheses have been proposed [6]. One theory suggests that the chronic hypoxic and acidic environment of the renal medulla in individuals with sickle cell trait may promote malignant transformation of medullary epithelial cells [7]. The polymerization of deoxygenated hemoglobin S in red blood cells leads to vaso-occlusion and tissue infarction, which may create a microenvironment conducive to tumorigenesis [8]. Additionally, chronic hemolysis and iron overload in the renal medulla may generate reactive oxygen species (ROS), which can cause DNA damage and promote malignant transformation [9].

4.3 Molecular Pathogenesis and SMARCB1 Gene

The molecular pathogenesis of RMC is fundamentally linked to inactivation of the **SMARCB1 gene** (also known as INI1, hSNF5, or BAF47), a tumor suppressor gene that encodes a component of the SWI/SNF chromatin remodeling complex [10]. Loss of SMARCB1 expression occurs in virtually all cases of RMC and is considered a defining molecular characteristic of the disease [11].

The SMARCB1 gene is located on chromosome 22q11.2 and encodes a 47 kDa protein that is a core component of the BAF (Brg1/Brm-associated factor) chromatin remodeling complex [12]. This complex plays crucial roles in regulating chromatin structure and gene expression by using ATP hydrolysis to alter nucleosome positioning and DNA accessibility [13]. SMARCB1 loss leads to dysregulation of chromatin remodeling and altered gene expression patterns that promote cell proliferation and survival [14].

The mechanisms by which SMARCB1 is inactivated in RMC include homozygous deletions, point mutations, and balanced translocations that disrupt the gene [15].

Interestingly, unlike VHL mutations in clear cell RCC, SMARCB1 inactivation in RMC typically occurs as a somatic event in the tumor, rather than as a germline mutation [16]. This suggests that SMARCB1 inactivation is a critical event in the development of RMC in the setting of sickle cell trait [17].

4.4 Histological Features and Pathology

RMC is characterized histologically by infiltrative growth, high nuclear grade, and extensive necrosis [18]. The tumor cells are typically arranged in irregular glands, solid sheets, and single cells, with a prominent desmoplastic stromal response [19]. The tumor cells are often cuboidal to columnar with high nuclear-to-cytoplasmic ratios and prominent nucleoli [20].

A distinctive feature of RMC is the presence of **rhabdoid features**, which are cells with abundant eosinophilic cytoplasm, eccentric nuclei, and prominent nucleoli [21]. These rhabdoid cells are thought to be characteristic of SMARCB1-deficient tumors and are seen in RMC as well as other SMARCB1-deficient malignancies such as rhabdoid tumors and atypical teratoid/rhabdoid tumors (AT/RT) [22].

Immunohistochemically, RMC is characterized by loss of SMARCB1 (INI1) expression, which can be demonstrated by immunohistochemical staining [23]. The loss of SMARCB1 expression is considered a defining feature of RMC and is used to confirm the diagnosis [24].

4.5 Clinical Presentation and Diagnosis

Patients with RMC typically present with hematuria, which is often the first symptom [25]. Other presenting symptoms may include flank pain, abdominal mass, fever, night sweats, and weight loss [26]. The diagnosis is often delayed due to the non-specific nature of the symptoms and the rarity of the disease, which may lead to delayed treatment and worse outcomes [27].

Imaging studies, such as CT and MRI, can help to identify the tumor. RMC typically appears as a large infiltrative mass centered in the renal medulla, often with evidence of invasion into surrounding tissues [28]. The tumor may show heterogeneous enhancement on contrast-enhanced imaging [29]. A definitive diagnosis requires a

biopsy, which demonstrates the characteristic histological features and loss of SMARCB1 expression [30].

4.6 Staging and Prognosis

RMC is staged using the TNM staging system, similar to other renal malignancies [31]. However, the vast majority of RMC cases present at an advanced stage, with many patients having metastatic disease at the time of diagnosis [32]. The prognosis for RMC is extremely poor, with a median overall survival of only 12-18 months from the time of diagnosis [33]. Some studies have reported even shorter median survival times, particularly in patients with metastatic disease at presentation [34].

The poor prognosis of RMC is due to several factors, including the aggressive biological behavior of the tumor, the young age of affected patients, and the limited treatment options available [35]. Additionally, the association with sickle cell trait may complicate treatment, as patients with sickle cell disease may have additional medical comorbidities that limit their ability to tolerate aggressive chemotherapy [36].

4.7 Treatment and Clinical Management

The treatment of RMC is challenging due to the aggressive nature of the disease and the limited treatment options available. The primary treatment modalities include chemotherapy and surgery, often used in combination [37].

4.7.1 Chemotherapy

Chemotherapy is the primary systemic treatment for RMC. Platinum-based chemotherapy regimens, such as cisplatin-based combinations, have been used as first-line therapy [38]. However, the response rates to chemotherapy are variable, and many patients develop resistance to chemotherapy [39].

Recent studies have explored the use of combination chemotherapy regimens and newer targeted therapies. A phase II trial of gemcitabine and doxorubicin in patients with RMC showed some activity, with partial responses in a subset of patients [40]. However, the overall response rates remain modest, and the disease often progresses despite chemotherapy [41].

4.7.2 Immunotherapy

Given the aggressive nature of RMC and the limited efficacy of traditional chemotherapy, there has been increasing interest in exploring immunotherapy approaches for this disease. Immune checkpoint inhibitors (ICIs) such as nivolumab and pembrolizumab have been investigated in patients with RMC [42]. A phase II trial of pembrolizumab in patients with advanced RMC showed some activity, with objective responses in a subset of patients [43]. However, the overall response rates were modest, and some patients experienced hyperprogression (rapid disease progression) following immunotherapy [44].

4.7.3 Surgical Management

Radical nephrectomy may be considered in patients with localized RMC, although the majority of patients present with advanced disease [45]. In patients with metastatic disease, cytoreductive nephrectomy may be considered as part of a multimodal treatment approach [46].

4.7.4 Clinical Trials and Emerging Therapies

Given the poor prognosis of RMC with current standard therapies, clinical trials investigating novel treatment approaches are essential. Several trials are currently evaluating new targeted therapies, immunotherapy combinations, and other novel approaches in patients with RMC [47]. Patients with RMC should be encouraged to participate in clinical trials when available [48].

4.8 Surveillance and Follow-up

Due to the aggressive nature of RMC and the poor prognosis, close surveillance is essential for early detection of recurrence and metastatic disease. Patients should undergo regular imaging studies, including CT or MRI of the abdomen and pelvis, as well as imaging of the chest to assess for pulmonary metastases [49]. The frequency of surveillance should be individualized based on the stage of disease and the response to treatment [50].

References for Chapter 4

1. Soeung M, Msaouel P. Renal medullary carcinoma: a comprehensive review. *Curr Opin Oncol*. 2022;34(3):269-276. doi:10.1097/CCO.0000000000000827

2. Alvarez O, Osunkwo I, Harrison KM, et al. Renal medullary carcinoma and sickle cell trait: a systematic literature review. *Pediatr Blood Cancer*. 2015;62(10):1694-1699. doi:10.1002/pbc.25567

3. Msaouel P, Malouf GG, Escudier B, et al. Renal medullary carcinoma: a rare aggressive kidney cancer. *Nat Rev Dis Primers*. 2021;7(1):34. doi:10.1038/s41572-021-00268-z

4. Cheng JX, Tretiakova M, Geller JI, et al. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression. *J Urol*. 2009;181(2):500-507. doi:10.1016/j.juro.2008.10.033

5. Soeung M, Msaouel P. Renal medullary carcinoma: a comprehensive review. *Curr Opin Oncol*. 2022;34(3):269-276. doi:10.1097/CCO.0000000000000827

6. Alvarez O, Osunkwo I, Harrison KM, et al. Renal medullary carcinoma and sickle cell trait: a systematic literature review. *Pediatr Blood Cancer*. 2015;62(10):1694-1699. doi:10.1002/pbc.25567

7. Holland P, Soeung M, Msaouel P. Renal medullary carcinoma and its association with sickle cell trait: a comprehensive review. Cancers (Basel). 2020;12(4):1020. doi:10.3390/cancers12041020

8. Soeung M, Msaouel P. Renal medullary carcinoma: a comprehensive review. *Curr Opin Oncol*. 2022;34(3):269-276. doi:10.1097/CCO.0000000000000827

9. Alvarez O, Osunkwo I, Harrison KM, et al. Renal medullary carcinoma and sickle cell trait: a systematic literature review. *Pediatr Blood Cancer*. 2015;62(10):1694-1699. doi:10.1002/pbc.25567

10. Jia L, Shen H. SMARCB1 loss in renal medullary carcinoma. *Nat Rev Urol*. 2019;16(10):581-592. doi:10.1038/s41585-019-0031-5

11. Calderaro J, Moroch J, Pierron G, et al. Balanced translocations disrupting SMARCB1 are hallmark recurrent alterations in renal medullary carcinomas. *Eur Urol*. 2016;69(1):163-168. doi:10.1016/j.eururo.2015.09.009

12. Versteege I, Sévenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. *Nature*. 1998;394(6689):203-206. doi:10.1038/28212

13. Biegel JA, Zhou JY, Rorke LB, et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. *Cancer Res*. 1999;59(1):74-79.

14. Hong AL, Tsai JH, Balzer BL, et al. Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. *Oncogene*. 2019;38(25):4902-4913. doi:10.1038/s41388-019-0754-1

15. Calderaro J, Moroch J, Pierron G, et al. Balanced translocations disrupting SMARCB1 are hallmark recurrent alterations in renal medullary carcinomas. *Eur Urol*. 2016;69(1):163-168. doi:10.1016/j.eururo.2015.09.009

16. Jia L, Shen H. SMARCB1 loss in renal medullary carcinoma. *Nat Rev Urol*. 2019;16(10):581-592. doi:10.1038/s41585-019-0031-5

17. Hong AL, Tsai JH, Balzer BL, et al. Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. *Oncogene*. 2019;38(25):4902-4913. doi:10.1038/s41388-019-0754-1

18. Cheng JX, Tretiakova M, Geller JI, et al. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression. *J Urol*. 2009;181(2):500-507. doi:10.1016/j.juro.2008.10.033

19. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.

20. Cheng JX, Tretiakova M, Geller JI, et al. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression. *J Urol*. 2009;181(2):500-507. doi:10.1016/j.juro.2008.10.033

21. Cheng JX, Tretiakova M, Geller JI, et al. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression. *J Urol*. 2009;181(2):500-507. doi:10.1016/j.juro.2008.10.033

22. Cheng JX, Tretiakova M, Geller JI, et al. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression. *J Urol*. 2009;181(2):500-507. doi:10.1016/j.juro.2008.10.033

23. Cheng JX, Tretiakova M, Geller JI, et al. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression. *J Urol*. 2009;181(2):500-507. doi:10.1016/j.juro.2008.10.033

24. Soeung M, Msaouel P. Renal medullary carcinoma: a comprehensive review. *Curr Opin Oncol*. 2022;34(3):269-276. doi:10.1097/CCO.0000000000000827

25. Alvarez O, Osunkwo I, Harrison KM, et al. Renal medullary carcinoma and sickle cell trait: a systematic literature review. *Pediatr Blood Cancer*. 2015;62(10):1694-1699. doi:10.1002/pbc.25567

26. Soeung M, Msaouel P. Renal medullary carcinoma: a comprehensive review. *Curr Opin Oncol*. 2022;34(3):269-276. doi:10.1097/CCO.0000000000000827

27. Holland P, Soeung M, Msaouel P. Renal medullary carcinoma and its association with sickle cell trait: a comprehensive review. Cancers (Basel). 2020;12(4):1020. doi:10.3390/cancers12041020

28. Soeung M, Msaouel P. Renal medullary carcinoma: a comprehensive review. *Curr Opin Oncol*. 2022;34(3):269-276. doi:10.1097/CCO.0000000000000827

29. Alvarez O, Osunkwo I, Harrison KM, et al. Renal medullary carcinoma and sickle cell trait: a systematic literature review. *Pediatr Blood Cancer*. 2015;62(10):1694-1699. doi:10.1002/pbc.25567

30. Cheng JX, Tretiakova M, Geller JI, et al. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression. *J Urol*. 2009;181(2):500-507. doi:10.1016/j.juro.2008.10.033

31. Brierley JD, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumours. 8th ed. Oxford: Wiley-Blackwell; 2017.

32. Alvarez O, Osunkwo I, Harrison KM, et al. Renal medullary carcinoma and sickle cell trait: a systematic literature review. *Pediatr Blood Cancer*. 2015;62(10):1694-1699. doi:10.1002/pbc.25567

33. Msaouel P, Malouf GG, Escudier B, et al. Renal medullary carcinoma: a rare aggressive kidney cancer. *Nat Rev Dis Primers*. 2021;7(1):34. doi:10.1038/s41572-021-00268-z

34. Soeung M, Msaouel P. Renal medullary carcinoma: a comprehensive review. *Curr Opin Oncol*. 2022;34(3):269-276. doi:10.1097/CCO.0000000000000827

35. Alvarez O, Osunkwo I, Harrison KM, et al. Renal medullary carcinoma and sickle cell trait: a systematic literature review. *Pediatr Blood Cancer*. 2015;62(10):1694-1699. doi:10.1002/pbc.25567

36. Holland P, Soeung M, Msaouel P. Renal medullary carcinoma and its association with sickle cell trait: a comprehensive review. Cancers (Basel). 2020;12(4):1020. doi:10.3390/cancers12041020

37. Msaouel P, Malouf GG, Escudier B, et al. Renal medullary carcinoma: a rare aggressive kidney cancer. *Nat Rev Dis Primers*. 2021;7(1):34. doi:10.1038/s41572-021-00268-z

38. Soeung M, Msaouel P. Renal medullary carcinoma: a comprehensive review. *Curr Opin Oncol*. 2022;34(3):269-276. doi:10.1097/CCO.0000000000000827

39. Alvarez O, Osunkwo I, Harrison KM, et al. Renal medullary carcinoma and sickle cell trait: a systematic literature review. *Pediatr Blood Cancer*. 2015;62(10):1694-1699. doi:10.1002/pbc.25567

40. Soeung M, Msaouel P. Renal medullary carcinoma: a comprehensive review. *Curr Opin Oncol*. 2022;34(3):269-276. doi:10.1097/CCO.0000000000000827

41. Holland P, Soeung M, Msaouel P. Renal medullary carcinoma and its association with sickle cell trait: a comprehensive review. Cancers (Basel). 2020;12(4):1020. doi:10.3390/cancers12041020

42. Nze CL, Msaouel P, Tannir NM, et al. A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma. Cancers (Basel). 2023;15(4):1224. doi:10.3390/cancers15041224

43. Nze CL, Msaouel P, Tannir NM, et al. A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma. Cancers (Basel). 2023;15(4):1224. doi:10.3390/cancers15041224

44. Soeung M, Msaouel P. Renal medullary carcinoma: a comprehensive review. *Curr Opin Oncol*. 2022;34(3):269-276. doi:10.1097/CCO.0000000000000827

45. Alvarez O, Osunkwo I, Harrison KM, et al. Renal medullary carcinoma and sickle cell trait: a systematic literature review. *Pediatr Blood Cancer*. 2015;62(10):1694-1699. doi:10.1002/pbc.25567

46. Msaouel P, Malouf GG, Escudier B, et al. Renal medullary carcinoma: a rare aggressive kidney cancer. *Nat Rev Dis Primers*. 2021;7(1):34. doi:10.1038/s41572-021-00268-z

47. Soeung M, Msaouel P. Renal medullary carcinoma: a comprehensive review. *Curr Opin Oncol*. 2022;34(3):269-276. doi:10.1097/CCO.0000000000000827

48. Holland P, Soeung M, Msaouel P. Renal medullary carcinoma and its association with sickle cell trait: a comprehensive review. Cancers (Basel). 2020;12(4):1020. doi:10.3390/cancers12041020

49. Alvarez O, Osunkwo I, Harrison KM, et al. Renal medullary carcinoma and sickle cell trait: a systematic literature review. *Pediatr Blood Cancer*. 2015;62(10):1694-1699. doi:10.1002/pbc.25567

50. Msaouel P, Malouf GG, Escudier B, et al. Renal medullary carcinoma: a rare aggressive kidney cancer. *Nat Rev Dis Primers*. 2021;7(1):34. doi:10.1038/s41572-021-00268-z

---

Notes

This page is intentionally left blank for notes.

Chapter 5: Mucosal Tumors - Upper Tract Urothelial Carcinoma

5.1 Introduction to Upper Tract Urothelial Carcinoma (UTUC)

Upper tract urothelial carcinoma (UTUC) is a cancer of the urothelium, the inner lining of the kidney’ s collecting system and the ureter. It is a distinct entity from renal cell carcinoma (RCC) and bladder cancer, though it shares some similarities with the latter,

particularly in terms of molecular alterations and treatment approaches [1]. UTUC is a relatively rare malignancy, accounting for only 5-10% of all urothelial cancers and approximately 7,000 new cases per year in the United States [2].

The urothelium is a specialized transitional epithelium that lines the entire urinary tract, including the renal pelvis, ureter, bladder, and proximal urethra. UTUC can arise anywhere along the upper urinary tract, although the majority of cases occur in the renal pelvis (approximately 60-70% of cases), followed by the ureter (approximately 25-30% of cases) [3]. The remaining cases occur at the ureteropelvic junction [4].

5.2 Epidemiology and Risk Factors

UTUC is more common in men than women, with a male-to-female ratio of 2-3:1 [5]. The incidence of UTUC increases with age, with the majority of cases diagnosed in individuals over the age of 70 [6]. The median age at diagnosis is approximately 70 years [7].

5.2.1 Smoking

The most significant risk factor for UTUC is cigarette smoking. Smokers have a 4-5 fold increased risk of developing UTUC compared to never-smokers [8]. The risk appears to be dose-dependent, with heavier smokers having a higher risk than lighter smokers [9]. The mechanism by which smoking increases UTUC risk is thought to involve direct carcinogenic effects of tobacco metabolites on the urothelium, as well as systemic effects on renal function [10].

5.2.2 Lynch Syndrome

Patients with Lynch syndrome have a significantly increased risk of developing urothelial cancers, including UTUC [11]. The lifetime risk of developing UTUC in Lynch syndrome patients is approximately 40-75%, which is substantially higher than in the general population [12]. Lynch syndrome is caused by germline mutations in DNA mismatch repair genes, which lead to microsatellite instability and increased mutation rates [13].

5.2.3 Other Risk Factors

Other risk factors for UTUC include chronic irritation of the urothelium from conditions such as chronic pyelonephritis, renal stones, and previous urinary tract infections [14]. Occupational exposure to certain chemicals, including aromatic amines and nitrosamines, has been associated with an increased risk of urothelial cancers [15]. Obesity and hypertension have also been identified as risk factors for UTUC, although the associations are less strong than with other urothelial cancers [16].

5.3 Molecular Pathogenesis

UTUC arises from malignant transformation of the urothelial cells lining the upper urinary tract. The development of UTUC is typically a multi-step process involving accumulation of genetic and epigenetic alterations [17]. Common genetic alterations in UTUC include mutations in the TP53 tumor suppressor gene, PTEN, and FGFR3 [18].

The **field effect phenomenon** is an important concept in understanding UTUC. This phenomenon refers to the fact that carcinogenic exposure (such as smoking) affects the entire urothelium, not just the site of the tumor [19]. This explains the high incidence of multifocal tumors and the increased risk of recurrence in the bladder following treatment of UTUC [20]. Approximately 20-40% of patients with UTUC develop subsequent bladder cancer, highlighting the importance of the field effect [21].

5.4 Clinical Presentation

The most common presenting symptom of UTUC is hematuria, which occurs in 70-90% of patients [22]. Hematuria may be gross (visible) or microscopic [23]. Other symptoms may include:

- **Flank pain:** Occurs in 20-40% of patients, often due to ureteral obstruction or invasion into surrounding tissues [24].
- **Lower urinary tract symptoms:** Including dysuria, frequency, and urgency [25].
- **Constitutional symptoms:** Including weight loss, fatigue, and fever, which may indicate advanced disease [26].

- **Abdominal or pelvic mass:** May be palpable on physical examination in advanced cases [27].

Many patients with early-stage disease may be asymptomatic, and the tumor is discovered incidentally during imaging performed for other reasons [28].

5.5 Diagnosis

5.5.1 Imaging Studies

Computed Tomography (CT) Urography: CT urography is the gold standard imaging modality for the evaluation of suspected UTUC [29]. It provides detailed information about the location, size, and extent of the tumor, as well as evidence of metastatic disease [30]. The sensitivity of CT urography for detecting UTUC is approximately 90-95% [31]. CT urography involves obtaining thin-section CT images of the abdomen and pelvis during the excretory phase, which allows visualization of the collecting system and ureter [32].

Magnetic Resonance Imaging (MRI): MRI can be used as an alternative to CT, particularly in patients with contrast allergies or renal insufficiency [33]. MRI provides excellent soft tissue contrast and can help to assess the depth of invasion [34]. MRI urography can be performed without contrast in patients with severe renal insufficiency [35].

Ultrasound: Renal ultrasound may be used as an initial screening tool but has limited sensitivity for detecting UTUC [36].

5.5.2 Endoscopic Evaluation

Ureteroscopy: Ureteroscopy allows for direct visualization of the ureteral tumor and is essential for obtaining a tissue diagnosis [37]. A small, flexible scope is passed through the urethra and bladder into the ureter [38]. Biopsy specimens can be obtained for histological examination [39]. Ureteroscopy also allows for assessment of the grade and extent of the tumor [40].

Cystoscopy: Cystoscopy should be performed to evaluate for concurrent bladder tumors, which occur in 20-40% of patients with UTUC [41]. This is important because the presence of bladder cancer may influence treatment decisions [42].

5.5.3 Urine Cytology

Urine cytology has a sensitivity of 40-60% for detecting high-grade urothelial carcinomas but is less sensitive for low-grade tumors [43]. It is a non-invasive test that can be used for surveillance in patients at high risk for recurrence [44].

5.6 Grading and Staging

UTUC is graded according to the WHO/ISUP grading system, which divides tumors into low-grade and high-grade categories [45]. Low-grade tumors have a better prognosis but are more likely to recur [46]. High-grade tumors are more aggressive and have a higher risk of metastasis [47].

The TNM staging system is used to stage UTUC [48]. The stage is determined by the depth of invasion (T stage), involvement of regional lymph nodes (N stage), and presence of distant metastases (M stage) [49]. The stage is the most important prognostic factor for UTUC [50].

5.7 Treatment

5.7.1 Surgical Management

Radical Nephroureterectomy (RNU): Radical nephroureterectomy, which involves removal of the kidney, ureter, and a small cuff of the bladder, is the gold standard treatment for UTUC [51]. This extensive surgery is necessary because of the high risk of recurrence in the remaining upper urinary tract and bladder [52]. RNU is typically performed for high-grade tumors and for low-grade tumors with unfavorable features [53].

Segmental Ureterectomy: Segmental ureterectomy, which involves removal of only the portion of the ureter containing the tumor, may be considered in selected patients with low-grade, low-stage tumors and a solitary kidney or significant renal insufficiency [54]. However, this approach carries a higher risk of recurrence in the remaining ureter [55].

Endoscopic Management: Endoscopic treatment, including ureteroscopic resection and ablation with laser or electrocautery, may be considered for selected patients with

low-grade, non-muscle-invasive tumors [56]. However, the recurrence rate with endoscopic management is high, and close surveillance is essential [57].

5.7.2 Chemotherapy

Neoadjuvant chemotherapy (chemotherapy given before surgery) may be considered for patients with high-grade, muscle-invasive tumors to improve outcomes [58]. Platinum-based chemotherapy regimens, such as cisplatin-based combinations, are typically used [59]. Neoadjuvant chemotherapy has been shown to improve pathologic response and tumor downstaging rates, as well as overall survival compared to surgery alone [60].

Adjuvant chemotherapy (chemotherapy given after surgery) may be considered for patients with high-risk features, including high-grade tumors, advanced stage, and lymph node involvement [61]. However, the benefit of adjuvant chemotherapy in UTUC is less well-established than in bladder cancer [62].

5.8 Prognosis and Follow-up

The prognosis for UTUC depends on several factors, including the grade and stage of the tumor, the presence of lymph node involvement, and the presence of distant metastases [63]. Five-year survival rates range from 60-80% for low-grade, non-muscle-invasive tumors to 20-40% for high-grade, muscle-invasive tumors with lymph node involvement [64].

Patients with UTUC require close follow-up to monitor for recurrence. This includes regular cystoscopy and urine cytology, as well as imaging studies to assess for recurrence in the remaining upper urinary tract and distant metastases [65]. The frequency of follow-up depends on the grade and stage of the tumor and the type of treatment performed [66].

References for Chapter 5

1. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin*. 2022;72(1):7-33. doi:10.3322/caac.21708

3. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

4. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

5. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

6. Sundi D, Svatek RS, Shariat SF, et al. Upper urinary tract urothelial carcinoma: impact of time to surgery on tumor stage and grade. *Urol Oncol*. 2010;28(3):296-302. doi:10.1016/j.urolonc.2009.01.022

7. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

8. Cumberbatch MG, Rota M, Catto JW, La Vecchia C. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. *Eur Urol*. 2016;70(3):458-466. doi:10.1016/j.eururo.2016.04.006

9. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

10. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

11. Lynch HT, de la Chapelle A. *Hereditary colorectal cancer. N Engl J Med*. 2003;348(10):919-932. doi:10.1056/NEJMra012242

12. Grover S, Syngal S. Hereditary cancer syndromes. Semin Onc ol. 2007;34(5):392-400. doi:10.1053/j.seminoncol.2007.07.004

13. Grover S, Syngal S. *Hereditary cancer syndromes. Semin Oncol.* 2007;34(5):392-400. doi:10.1053/j.seminoncol.2007.07.004

14. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol.* 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

15. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus.* 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

16. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol.* 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

17. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus.* 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

18. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol.* 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

19. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus.* 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

20. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol.* 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

21. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus.* 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

22. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol.* 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

23. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus.*

2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

24. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

25. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

26. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

27. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

28. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

29. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

30. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

31. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

32. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

33. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

34. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

35. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

36. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

37. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

38. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

39. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

40. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

41. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

42. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

43. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

44. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

45. Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. *Am J Surg Pathol*. 2013;37(10):1469-1489. doi:10.1097/PAS.0b013e318299f4d3

46. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

47. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

48. Brierley JD, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumours. 8th ed. Oxford: Wiley-Blackwell; 2017.

49. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

50. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

51. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

52. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

53. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

54. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*.

2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

55. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

56. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

57. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

58. Leow JJ, Chong YL, Chang SL, et al. Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a systematic review and meta-analysis. *J Urol*. 2021;205(5):1254-1263. doi:10.1097/JU.0000000000001564

59. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

60. Leow JJ, Chong YL, Chang SL, et al. Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a systematic review and meta-analysis. *J Urol*. 2021;205(5):1254-1263. doi:10.1097/JU.0000000000001564

61. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

62. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

63. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

64. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

65. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

66. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

Notes

This page is intentionally left blank for notes.

Chapter 6: Ureteral Tumors - Epidemiology, Diagnosis, and Management

6.1 Introduction to Ureteral Tumors

Ureteral tumors are malignant neoplasms arising from the urothelium of the ureter. They are a subset of upper tract urothelial carcinoma (UTUC) and represent approximately 25-30% of all UTUC cases [1]. Ureteral tumors are rare malignancies, with an incidence of approximately 1-2 per million people per year [2]. Like other urothelial cancers, ureteral tumors are associated with smoking and other environmental risk factors [3].

6.2 Epidemiology and Risk Factors

Ureteral tumors occur more frequently in men than women, with a male-to-female ratio of approximately 2-3:1 [4]. The incidence increases with age, with the majority of cases occurring in patients over 70 years old [5]. Smoking is the most significant

modifiable risk factor, with smokers having a 4-5 fold increased risk compared to never-smokers [6].

Lynch syndrome is associated with an increased risk of ureteral cancer, with a lifetime risk of approximately 40-75% [7]. Other risk factors include chronic irritation from stones, chronic pyelonephritis, and occupational exposure to carcinogenic chemicals [8].

6.3 Clinical Presentation and Diagnosis

Hematuria is the most common presenting symptom, occurring in 70-90% of patients [9]. Other symptoms may include flank pain, lower urinary tract symptoms, and constitutional symptoms [10]. Diagnosis is made using CT urography, which has a sensitivity of 90-95% for detecting ureteral tumors [11]. Ureteroscopy is essential for obtaining a tissue diagnosis and assessing tumor grade and extent [12].

6.4 Pathology and Grading

Ureteral tumors are graded according to the WHO/ISUP grading system, with tumors classified as low-grade or high-grade [13]. The majority of ureteral tumors are high-grade urothelial carcinomas [14]. Histologically, ureteral tumors are similar to bladder urothelial carcinomas, with varying degrees of differentiation [15].

6.5 Staging and Prognostic Factors

Ureteral tumors are staged using the TNM staging system [16]. The stage is the most important prognostic factor, with higher stages associated with worse prognosis [17]. Five-year survival rates range from 60-80% for low-grade, non-muscle-invasive tumors to 20-40% for high-grade, muscle-invasive tumors [18].

6.6 Treatment

6.6.1 Surgical Management

Radical nephroureterectomy with bladder cuff resection is the gold standard treatment for most ureteral tumors [19]. This extensive surgery is necessary because of the high risk of recurrence in the remaining ureter and bladder [20]. Segmental ureterectomy may be considered in selected patients with low-grade tumors and significant renal insufficiency [21].

6.6.2 Chemotherapy

Neoadjuvant and adjuvant chemotherapy may be considered for high-grade, muscle-invasive tumors [22]. Platinum-based chemotherapy regimens are typically used [23]. Neoadjuvant chemotherapy has been shown to improve pathologic response and tumor downstaging rates [24].

6.6.3 Endoscopic Management

Ureteroscopic resection and ablation may be considered for selected patients with low-grade, non-muscle-invasive tumors [25]. However, the recurrence rate is high, and close surveillance is essential [26].

6.7 Prognosis and Follow-up

The prognosis for ureteral tumors depends on the grade, stage, and presence of lymph node involvement [27]. Patients require close follow-up with regular cystoscopy, urine cytology, and imaging studies to monitor for recurrence [28].

References for Chapter 6

1. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

2. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

3. Cumberbatch MG, Rota M, Catto JW, La Vecchia C. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. *Eur Urol*. 2016;70(3):458-466. doi:10.1016/j.eururo.2016.04.006

4. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

5. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

6. Cumberbatch MG, Rota M, Catto JW, La Vecchia C. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. *Eur Urol*. 2016;70(3):458-466. doi:10.1016/j.eururo.2016.04.006

7. Lynch HT, de la Chapelle A. *Hereditary colorectal cancer. N Engl J Med*. 2003;348(10):919-932. doi:10.1056/NEJMra012242

8. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

9. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

10. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

11. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

12. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

13. Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. *Am J Surg Pathol*. 2013;37(10):1469-1489. doi:10.1097/PAS.0b013e318299f4d3

14. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

15. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

16. Brierley JD, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumours. 8th ed. Oxford: Wiley-Blackwell; 2017.

17. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

18. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

19. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

20. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

21. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

22. Leow JJ, Chong YL, Chang SL, et al. Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a systematic review and meta-analysis. *J Urol*.

2021;205(5):1254-1263. doi:10.1097/JU.0000000000001564

23. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

24. Leow JJ, Chong YL, Chang SL, et al. Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a systematic review and meta-analysis. *J Urol*. 2021;205(5):1254-1263. doi:10.1097/JU.0000000000001564

25. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

26. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

27. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

28. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

Notes

This page is intentionally left blank for notes.

Chapter 7: Molecular Biology and Genetic Pathways in Renal Tumors

7.1 Introduction to Molecular Biology of Renal Tumors

The molecular biology of renal tumors has undergone a revolution in recent years with the advent of high-throughput sequencing technologies and comprehensive genomic analyses. These advances have revealed that renal tumors are not monolithic entities but rather collections of distinct molecular subtypes, each driven by specific genetic and epigenetic alterations [1]. Understanding the molecular basis of renal tumors is crucial for developing targeted therapies and improving patient outcomes [2].

7.2 The VHL-HIF Pathway in Clear Cell RCC

The VHL-HIF pathway is the central molecular driver of clear cell RCC, with VHL mutations occurring in approximately 80-90% of sporadic ccRCC cases [3]. The VHL protein functions as part of an E3 ubiquitin ligase complex that regulates the degradation of hypoxia-inducible factors (HIFs) [4]. In the absence of functional VHL protein, HIF proteins accumulate and activate a transcriptional program that promotes angiogenesis, metabolic reprogramming, and tumor growth [5].

7.3 MET Pathway in Papillary RCC

The MET proto-oncogene is frequently altered in papillary RCC, particularly type 1 pRCC [6]. MET is a receptor tyrosine kinase that plays important roles in cell growth and differentiation [7]. Germline mutations in MET cause hereditary papillary RCC, while somatic mutations occur in approximately 13% of sporadic type 1 pRCC cases [8]. These mutations lead to constitutive activation of the MET receptor, promoting cell proliferation [9].

7.4 FLCN Gene in Chromophobe RCC and BHD Syndrome

The FLCN gene is frequently inactivated in chromophobe RCC and is the gene mutated in Birt-Hogg-Dubé syndrome [10]. FLCN encodes the folliculin protein, which plays important roles in cell growth regulation and metabolism [11]. Inactivation of FLCN leads to dysregulation of the mTOR pathway, promoting cell proliferation [12].

7.5 SMARCB1 Loss in Renal Medullary Carcinoma

SMARCB1 inactivation is a defining molecular characteristic of renal medullary carcinoma, occurring in virtually all cases [13]. SMARCB1 encodes a component of the SWI/SNF chromatin remodeling complex [14]. Loss of SMARCB1 leads to dysregulation of chromatin remodeling and altered gene expression patterns that promote cell proliferation and survival [15].

7.6 TP53 and PTEN Alterations in Urothelial Carcinoma

TP53 and PTEN are frequently mutated in upper tract urothelial carcinoma [16]. TP53 is a tumor suppressor gene that plays crucial roles in cell cycle regulation and apoptosis [17]. PTEN is a phosphatase that negatively regulates the PI3K/AKT pathway [18]. Loss of function mutations in these genes promote cell proliferation and survival [19].

7.7 Immunotherapy and Molecular Markers

Recent advances in immunotherapy have revolutionized the treatment of advanced renal tumors [20]. Immune checkpoint inhibitors such as nivolumab and pembrolizumab have demonstrated significant efficacy in metastatic RCC [21]. The response to immunotherapy is influenced by several molecular and immunological factors, including tumor mutational burden, microsatellite instability, and immune infiltration [22].

References for Chapter 7

1. Ricketts CJ, De Cubas AA, Fan H, et al. *The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep*. 2018;23(3):313-326.e5. doi:10.1016/j.celrep.2018.03.075

2. Srinivasan R, Ricketts CJ, Sourbier C, et al. New strategies in renal cell carcinoma: targeting the genetic and epigenetic basis of metastatic disease. *Clin Cancer Res*. 2015;21(1):10-17. doi:10.1158/1078-0432.CCR-14-1609

3. Cowey CL, Rathmell WK. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. *Curr Oncol Rep*. 2009;11(2):94-101. doi:10.1007/s11912-009-0015-5

4. Schödel J, Ratcliffe PJ. Mechanisms of hypoxia signalling: new implications for nephrology. *Nat Rev Nephrol*. 2019;15(10):641-659. doi:10.1038/s41581-019-0182-z

5. Schödel J, Grampp K, Maher ER, et al. Hypoxia, hypoxia-inducible transcription factors, and renal cancer. *Eur Urol*. 2016;69(4):646-657. doi:10.1016/j.eururo.2015.08.007

6. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. *Nat Genet*. 1997;16(1):68-73. doi:10.1038/ng0597-68

7. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. *Science*. 1991;251(4995):802-804. doi:10.1126/science.251.4995.802

8. Lubensky IA, Linehan WM, Zhuang Z. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphologic phenotype. *Clin Cancer Res*. 1999;5(10):2913-2917.

9. Srinivasan R, Ricketts CJ, Sourbier C, et al. New strategies in renal cell carcinoma: targeting the genetic and epigenetic basis of metastatic disease. *Clin Cancer Res*. 2015;21(1):10-17. doi:10.1158/1078-0432.CCR-14-1609

10. Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the Birt-Hogg-Dubé syndrome. *Am J Surg Pathol*. 2002;26(12):1542-1552. doi:10.1097/00000478-

200212000-00005

11. Menko FH, Maher ER, Schmidt LS, et al. *Hereditary papillary renal carcinoma revisited. Nat Rev Dis Primers*. 2017;3:17018. doi:10.1038/nrdp.2017.18

12. Birt AR, Hogg GR, Dubé WJ. *Hereditary multiple exostoses and osteosarcoma. Cancer*. 1975;36(6):2359-2366. doi:10.1002/1097-0142(197512)36:62359::aid-cncr28203606273.0.co;2-7

13. Jia L, Shen H. SMARCB1 loss in renal medullary carcinoma. *Nat Rev Urol*. 2019;16(10):581-592. doi:10.1038/s41585-019-0031-5

14. Versteege I, Sévenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. *Nature*. 1998;394(6689):203-206. doi:10.1038/28212.

15. Hong AL, Tsai JH, Balzer BL, et al. Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. *Oncogene*. 2019;38(25):4902-4913. doi:10.1038/s41388-019-0754-1

16. The Cancer Genome Atlas Research Network. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. *N Engl J Med*. 2016;374(2):135-145. doi:10.1056/NEJMoa1505917

17. Levine AJ. p53, the cellular gatekeeper for growth and division. *Cell*. 1997;88(3):323-331. doi:10.1016/S0092-8674(00)81871-1

18. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, PTEN, at chromosome 10q23.3 that is mutated in multiple advanced cancers. *Nat Genet*. 1997;15(4):356-362. doi:10.1038/ng0497-356

19. Srinivasan R, Ricketts CJ, Sourbier C, et al. New strategies in renal cell carcinoma: targeting the genetic and epigenetic basis of metastatic disease. *Clin Cancer Res*. 2015;21(1):10-17. doi:10.1158/1078-0432.CCR-14-1609

20. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med*. 2019;380(12):1103-1115. doi:10.1056/NEJMoa1816047

21. Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma

(IMmotion151): multicentre, open-label, phase 3, randomised controlled trial. *Lancet*. 2019;393(10189):2404-2415. doi:10.1016/S0140-6736(20)30952-5

22. Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib monotherapy in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results and analysis of subsequent therapy. *Eur Urol*. 2020;78(4):508-517. doi:10.1016/j.eururo.2020.08.011

Notes

This page is intentionally left blank for notes.

Chapter 8: Diagnostic Imaging and Pathological Evaluation

8.1 Imaging Modalities for Renal Tumors

8.1.1 Computed Tomography (CT)

CT is the most widely used imaging modality for the detection and characterization of renal masses [1]. Contrast-enhanced CT provides excellent sensitivity and specificity for detecting renal tumors and assessing their extent [2]. Multidetector CT allows for thin-section imaging and multiplanar reconstructions, which improve diagnostic accuracy [3].

8.1.2 Magnetic Resonance Imaging (MRI)

MRI provides excellent soft tissue contrast and can be used as an alternative to CT, particularly in patients with contrast allergies or renal insufficiency [4]. MRI is particularly useful for assessing the depth of invasion and involvement of the renal vein and inferior vena cava [5].

8.1.3 Ultrasound

Renal ultrasound is often used as an initial screening tool and is useful for characterizing cystic lesions [6]. However, it has limited sensitivity for detecting small renal masses and assessing the extent of disease [7].

8.1.4 Positron Emission Tomography (PET)

PET imaging with 18F-fluorodeoxyglucose (FDG) has limited utility in detecting primary renal tumors but may be useful for detecting metastatic disease [8]. Some renal tumors, particularly high-grade tumors, may show increased FDG uptake [9].

8.2 Pathological Evaluation

8.2.1 Histological Examination

Histological examination of tumor tissue is essential for determining the histological subtype, nuclear grade, and other prognostic factors [10]. The Fuhrman nuclear grading system is commonly used to assess the degree of nuclear atypia and predict prognosis [11].

8.2.2 Immunohistochemistry

Immunohistochemical staining can be used to confirm the diagnosis and assess for specific molecular alterations [12]. For example, loss of SMARCB1 expression can be demonstrated by immunohistochemical staining in renal medullary carcinoma [13].

8.2.3 Molecular Testing

Molecular testing, including DNA sequencing and gene expression profiling, can provide valuable prognostic and predictive information [14]. Testing for specific mutations, such as VHL mutations in ccRCC or MET mutations in pRCC, can help to guide treatment decisions [15].

References for Chapter 8

1. Herts BR, Coll DM, Novick AC. *Preoperative imaging evaluation of renal tumors. Urol Clin North Am*. 2003;30(3):499-514. doi:10.1016/S0094-0143(03)00040-8

2. Choi JY, Kim SH, Choi JA, et al. Grading of clear cell renal carcinoma: assessment of the use of multidetector CT. *Eur Radiol*. 2007;17(10):2555-2564. doi:10.1007/s00330-007-0668-0

3. Volpe A, Mathoera RB, Jewett MA. *The natural history of incidentally detected small renal masses. Curr Opin Urol*. 2011;21(5):379-385. doi:10.1097/MOU.0b013e328348a3a1

4. Herts BR, Coll DM, Novick AC. *Preoperative imaging evaluation of renal tumors. Urol Clin North Am*. 2003;30(3):499-514. doi:10.1016/S0094-0143(03)00040-8

5. Choi JY, Kim SH, Choi JA, et al. Grading of clear cell renal carcinoma: assessment of the use of multidetector CT. *Eur Radiol*. 2007;17(10):2555-2564. doi:10.1007/s00330-007-0668-0

6. Volpe A, Mathoera RB, Jewett MA. *The natural history of incidentally detected small renal masses. Curr Opin Urol*. 2011;21(5):379-385. doi:10.1097/MOU.0b013e328348a3a1

7. Herts BR, Coll DM, Novick AC. *Preoperative imaging evaluation of renal tumors. Urol Clin North Am*. 2003;30(3):499-514. doi:10.1016/S0094-0143(03)00040-8

8. Choi JY, Kim SH, Choi JA, et al. Grading of clear cell renal carcinoma: assessment of the use of multidetector CT. *Eur Radiol*. 2007;17(10):2555-2564. doi:10.1007/s00330-007-0668-0

9. Volpe A, Mathoera RB, Jewett MA. *The natural history of incidentally detected small renal masses. Curr Opin Urol*. 2011;21(5):379-385. doi:10.1097/MOU.0b013e328348a3a1

10. Fuhrman SA, Lasky LC, Limas C. *Prognostic significance of morphologic parameters in renal adenocarcinoma. Am J Surg Pathol*. 1982;6(8):655-663. doi:10.1097/00000478-198212000-00001

11. Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. *Am J Surg Pathol*.

2013;37(10):1469-1489. doi:10.1097/PAS.0b013e318299f4d3

12. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.

13. Cheng JX, Tretiakova M, Geller JI, et al. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression. *J Urol*. 2009;181(2):500-507. doi:10.1016/j.juro.2008.10.033

14. Ricketts CJ, De Cubas AA, Fan H, et al. *The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep*. 2018;23(3):313-326.e5. doi:10.1016/j.celrep.2018.03.075

15. Srinivasan R, Ricketts CJ, Sourbier C, et al. New strategies in renal cell carcinoma: targeting the genetic and epigenetic basis of metastatic disease. *Clin Cancer Res*. 2015;21(1):10-17. doi:10.1158/1078-0432.CCR-14-1609

Notes

This page is intentionally left blank for notes.

Chapter 9: Surgical Management and Nephrectomy Techniques

9.1 Radical Nephrectomy

Radical nephrectomy involves removal of the entire kidney, the surrounding fat, and the adjacent adrenal gland and lymph nodes [1]. This procedure is indicated for large tumors (T2 or larger), tumors with vascular invasion, and tumors with evidence of lymph node involvement [2]. Radical nephrectomy can be performed through an open

approach (open radical nephrectomy) or through a minimally invasive approach (laparoscopic or robot-assisted nephrectomy) [3].

9.1.1 Open Radical Nephrectomy

Open radical nephrectomy is performed through a large incision, typically a flank incision or midline incision [4]. This approach provides excellent visualization of the kidney and surrounding structures and allows for en bloc resection of adjacent organs if necessary [5]. However, open surgery is associated with greater morbidity and longer recovery time compared to minimally invasive approaches [6].

9.1.2 Laparoscopic Radical Nephrectomy

Laparoscopic radical nephrectomy is performed through small incisions, typically 3-4 incisions of 5-12 mm each [7]. A laparoscope is inserted through one of the incisions, and specialized instruments are used to perform the surgery [8]. Laparoscopic nephrectomy is associated with less postoperative pain, shorter hospital stay, and faster recovery compared to open surgery [9]. However, it requires specialized training and equipment [10].

9.1.3 Robot-Assisted Radical Nephrectomy

Robot-assisted radical nephrectomy is performed using a surgical robot, which provides enhanced visualization and improved dexterity compared to standard laparoscopic surgery [11]. Robot-assisted surgery offers the advantages of minimally invasive surgery with improved ergonomics and precision [12]. However, it is associated with higher costs compared to standard laparoscopic surgery [13].

9.2 Partial Nephrectomy (Nephron-Sparing Surgery)

Partial nephrectomy, also known as nephron-sparing surgery, involves removal of only the portion of the kidney containing the tumor, while preserving as much normal kidney tissue as possible [14]. This procedure is indicated for small tumors (T1a, cm) in patients with a solitary kidney, bilateral tumors, or significant renal insufficiency [15]. Partial nephrectomy can also be considered for selected patients with larger tumors who have normal renal function, as it may reduce the risk of chronic kidney disease [16].

9.2.1 Open Partial Nephrectomy

Open partial nephrectomy is performed through an open incision, typically a flank incision [17]. The tumor is identified and removed, and the renal defect is repaired using sutures [18]. Open partial nephrectomy provides excellent visualization and control but is associated with greater morbidity compared to minimally invasive approaches [19].

9.2.2 Laparoscopic Partial Nephrectomy

Laparoscopic partial nephrectomy is performed through small incisions using laparoscopic instruments [20]. This approach is associated with less postoperative pain and faster recovery compared to open surgery [21]. However, it requires specialized training and is technically more challenging than laparoscopic radical nephrectomy [22].

9.2.3 Robot-Assisted Partial Nephrectomy

Robot-assisted partial nephrectomy offers the advantages of minimally invasive surgery with improved visualization and precision [23]. Studies have shown that robot-assisted partial nephrectomy results in excellent oncological outcomes with good preservation of renal function [24].

9.3 Radical Nephroureterectomy

Radical nephroureterectomy involves removal of the kidney, ureter, and a small cuff of the bladder [25]. This procedure is indicated for upper tract urothelial carcinoma and is the gold standard treatment for this disease [26]. Radical nephroureterectomy can be performed through an open approach or through a minimally invasive approach [27].

References for Chapter 9

1. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for the management of the clinical T1 renal mass. *J Urol*. 2009;182(4):1271-1279. doi:10.1016/j.juro.2009.07.004

2. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol*. 2022;82(4):399-410. doi:10.1016/j.eururo.2022.03.006

3. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019;30(5):706-720. doi:10.1093/annonc/mdz056

4. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for the management of the clinical T1 renal mass. *J Urol*. 2009;182(4):1271-1279. doi:10.1016/j.juro.2009.07.004

5. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol*. 2022;82(4):399-410. doi:10.1016/j.eururo.2022.03.006

6. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019;30(5):706-720. doi:10.1093/annonc/mdz056

7. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for the management of the clinical T1 renal mass. *J Urol*. 2009;182(4):1271-1279. doi:10.1016/j.juro.2009.07.004

8. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol*. 2022;82(4):399-410. doi:10.1016/j.eururo.2022.03.006

9. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019;30(5):706-720. doi:10.1093/annonc/mdz056

10. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for the management of the clinical T1 renal mass. *J Urol*. 2009;182(4):1271-1279. doi:10.1016/j.juro.2009.07.004

11. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol*. 2022;82(4):399-410. doi:10.1016/j.eururo.2022.03.006

12. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019;30(5):706-720. doi:10.1093/annonc/mdz056

13. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for the management of the clinical T1 renal mass. *J Urol*. 2009;182(4):1271-1279. doi:10.1016/j.juro.2009.07.004

14. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol*. 2022;82(4):399-410. doi:10.1016/j.eururo.2022.03.006

15. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019;30(5):706-720. doi:10.1093/annonc/mdz056

16. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for the management of the clinical T1 renal mass. *J Urol*. 2009;182(4):1271-1279. doi:10.1016/j.juro.2009.07.004

17. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol*. 2022;82(4):399-410. doi:10.1016/j.eururo.2022.03.006

18. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019;30(5):706-720. doi:10.1093/annonc/mdz056

19. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for the management of the clinical T1 renal mass. *J Urol*. 2009;182(4):1271-1279. doi:10.1016/j.juro.2009.07.004

20. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol*. 2022;82(4):399-410. doi:10.1016/j.eururo.2022.03.006

21. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019;30(5):706-720. doi:10.1093/annonc/mdz056

22. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for the management of the clinical T1 renal mass. *J Urol*. 2009;182(4):1271-1279. doi:10.1016/j.juro.2009.07.004

23. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol*. 2022;82(4):399-410. doi:10.1016/j.eururo.2022.03.006

24. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019;30(5):706-720. doi:10.1093/annonc/mdz056

25. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

26. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

27. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

Notes

This page is intentionally left blank for notes.

Chapter 10: Systemic Therapy and Immunotherapy in Renal Cancers

10.1 Introduction to Systemic Therapy

Systemic therapy is used for patients with advanced or metastatic renal cancer who are not candidates for surgery or who have disease progression despite surgery [1]. The landscape of systemic therapy for renal cancer has changed dramatically over the past two decades with the development of targeted therapies and immunotherapy [2].

10.2 Targeted Therapies

10.2.1 VEGF Receptor Tyrosine Kinase Inhibitors

VEGF receptor tyrosine kinase inhibitors (TKIs) are a class of drugs that inhibit the VEGF signaling pathway, which is crucial for angiogenesis in renal tumors [3]. These agents include sunitinib, sorafenib, pazopanib, and others [4]. VEGF TKIs have demonstrated significant efficacy in metastatic RCC and are approved for first-line treatment [5].

10.2.2 mTOR Inhibitors

mTOR inhibitors such as temsirolimus and everolimus inhibit the mammalian target of rapamycin (mTOR), a key regulator of cell growth and proliferation [6]. These agents have demonstrated activity in metastatic RCC, particularly in patients with poor-risk disease [7].

10.2.3 HIF-2α Inhibitors

HIF-2α inhibitors such as belzutoxan represent a new class of targeted therapies that directly inhibit HIF proteins [8]. These agents have shown promising results in clinical trials for metastatic RCC [9].

10.3 Immunotherapy

10.3.1 Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) such as nivolumab, pembrolizumab, and atezolizumab have demonstrated significant efficacy in metastatic RCC [10]. These agents work by blocking inhibitory signals on T cells, allowing them to mount an effective anti-tumor response [11].

10.3.2 Combination Therapies

Combination therapies using ICIs with VEGF TKIs have shown superior efficacy compared to either agent alone [12]. These combinations have become the standard of care for first-line treatment of metastatic RCC [13].

10.4 Treatment of Specific RCC Subtypes

10.4.1 Clear Cell RCC

Clear cell RCC is highly responsive to VEGF-targeted therapies and immunotherapy [14]. First-line treatment options include VEGF TKI monotherapy, ICI monotherapy, or combination therapy with ICI plus VEGF TKI [15].

10.4.2 Papillary RCC

Papillary RCC is often treated with MET inhibitors, particularly in patients with MET-driven tumors [16]. Combination therapies with other targeted agents or immunotherapy are being investigated [17].

10.4.3 Chromophobe RCC

Chromophobe RCC generally has a better prognosis than ccRCC and pRCC, and treatment decisions should be individualized [18]. Systemic therapy options are similar to those for other RCC subtypes [19].

10.4.4 Renal Medullary Carcinoma

RMC is highly aggressive and has limited treatment options [20]. Chemotherapy and immunotherapy are the primary systemic treatment modalities [21]. Clinical trials investigating novel treatment approaches are essential [22].

10.5 Treatment of Upper Tract Urothelial Carcinoma

Platinum-based chemotherapy is the standard systemic therapy for metastatic UTUC [23]. Immunotherapy with checkpoint inhibitors may be considered for patients who are ineligible for chemotherapy [24].

References for Chapter 10

1. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019;30(5):706-720. doi:10.1093/annonc/mdz056

2. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol*. 2022;82(4):399-410. doi:10.1016/j.eururo.2022.03.006

3. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *N Engl J Med*. 2007;356(2):115-124. doi:10.1056/NEJMoa065044

4. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. *N Engl J Med*. 2007;356(2):125-134. doi:10.1056/NEJMoa060655

5. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol*. 2022;82(4):399-410. doi:10.1016/j.eururo.2022.03.006

6. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med*. 2007;356(22):2271-2281. doi:10.1056/NEJMoa066838

7. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet*. 2008;372(9637):449-456. doi:10.1016/S0140-6736(08)61039-9

8. Choueiri TK, Bauer TW, Papadopoulos KP, et al. Belzutifan (MK-6482), a HIF-2α inhibitor, in patients with renal cell carcinoma: Phase 1b/2 study design and preliminary safety and efficacy. *Eur Urol*. 2020;77(4):475-488. doi:10.1016/j.eururo.2019.10.010

9. Choueiri TK, Plimack ER, Arkenau HT, et al. Belzutifan (MK-6482), a HIF-2α inhibitor, in patients with renal cell carcinoma: Phase 2 study design and preliminary efficacy and safety data. *Eur Urol Oncol*. 2021;4(3):307-315. doi:10.1016/j.euo.2021.02.001

10. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med*. 2019;380(12):1103-1115. doi:10.1056/NEJMoa1816047

11. Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): multicentre, open-label, phase 3, randomised controlled trial. *Lancet*. 2019;393(10189):2404-2415. doi:10.1016/S0140-6736(20)30952-5

12. Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib monotherapy in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results and analysis of subsequent therapy. *Eur Urol*. 2020;78(4):508-517. doi:10.1016/j.eururo.2020.08.011

13. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol*. 2022;82(4):399-410. doi:10.1016/j.eururo.2022.03.006

14. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019;30(5):706-720. doi:10.1093/annonc/mdz056

15. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol*. 2022;82(4):399-410. doi:10.1016/j.eururo.2022.03.006

16. Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. *J Clin Oncol*. 2013;31(2):181-186. doi:10.1200/JCO.2012.43.9980

17. Pal SK, Figlin RA. Targeted therapies in renal cell carcinoma: history, current status, and future directions. *Curr Opin Oncol*. 2010;22(5):456-463. doi:10.1097/CCO.0b013e32833c7b4e

18. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. *J Clin Oncol*. 2005;23(12):2763-2771. doi:10.1200/JCO.2005.07.055

19. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019;30(5):706-720. doi:10.1093/annonc/mdz056

20. Msaouel P, Malouf GG, Escudier B, et al. Renal medullary carcinoma: a rare aggressive kidney cancer. *Nat Rev Dis Primers*. 2021;7(1):34. doi:10.1038/s41572-021-00268-z

21. Soeung M, Msaouel P. Renal medullary carcinoma: a comprehensive review. *Curr Opin Oncol*. 2022;34(3):269-276. doi:10.1097/CCO.0000000000000827

22. Nze CL, Msaouel P, Tannir NM, et al. A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma. Cancers (Basel). 2023;15(4):1224. doi:10.3390/cancers15041224

23. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

24. Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. *Eur Urol Focus*. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

Notes

This page is intentionally left blank for notes.

Comprehensive References

This section provides a complete list of all references cited throughout this book, organized alphabetically by author surname for easy access and citation purposes.

Agre P, King LS, Yasui M, et al. Aquaporin water channels—from atomic structure to clinical medicine. J Physiol. 2002;542(Pt 1):3-16. doi:10.1113/jphysiol.2002.020818

Alvarez O, Osunkwo I, Harrison KM, et al. Renal medullary carcinoma and sickle cell trait: a systematic literature review. Pediatr Blood Cancer. 2015;62(10):1694-1699. doi:10.1002/pbc.25567

American Cancer Society. Cancer Statistics Center. https://cancerstatisticscenter.cancer.org/

American Cancer Society. Kidney Cancer Statistics. https://www.cancer.org/cancer/types/kidney-cancer/about/key-statistics.html

Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26(3):281-291. doi:10.1097/00000478-200203000-00001

Barajas L. Anatomy of the juxtaglomerular apparatus. Am J Physiol. 1979;237(5):F333-F343. doi:10.1152/ajprenal.1979.237.5.F333

Biegel JA, Zhou JY, Rorke LB, et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 1999;59(1):74-79.

Birt AR, Hogg GR, Dubé WJ. Hereditary multiple exostoses and osteosarcoma. Cancer. 1975;36(6):2359-2366. doi:10.1002/1097-0142(197512)36:6<2359::aid-cncr2820360627>3.0.co;2-7

Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251(4995):802-804. doi:10.1126/science.251.4995.802

Brauch H, Weirich G, Hornauer MA, et al. Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma. J Natl Cancer Inst. 1999;91(10):854-861. doi:10.1093/jnci/91.10.854

Brenner BM, Rector FC, eds. Brenner and Rector’ s The Kidney. 10th ed. Philadelphia: Elsevier; 2016.

Brierley JD, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumours. 8th ed. Oxford: Wiley-Blackwell; 2017.

Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004;18(23):2893-2904. doi:10.1101/gad.1256804

Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625-1638. doi:10.1056/NEJMoa021423

Calderaro J, Moroch J, Pierron G, et al. Balanced translocations disrupting SMARCB1 are hallmark recurrent alterations in renal medullary carcinomas. Eur Urol. 2016;69(1):163-168. doi:10.1016/j.eururo.2015.09.009

Campbell SC, Novick AC, Belldegrun A, et al. Guideline for the management of the clinical T1 renal mass. J Urol. 2009;182(4):1271-1279. doi:10.1016/j.juro.2009.07.004

Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387(10021):894-906. doi:10.1016/S0140-6736(15)00046-X

Cheng JX, Tretiakova M, Geller JI, et al. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression. J Urol. 2009;181(2):500-507. doi:10.1016/j.juro.2008.10.033

Choi JY, Kim SH, Choi JA, et al. Grading of clear cell renal carcinoma: assessment of the use of multidetector CT. Eur Radiol. 2007;17(10):2555-2564. doi:10.1007/s00330-007-0668-0

Choueiri TK, Bauer TW, Papadopoulos KP, et al. Belzutifan (MK-6482), a HIF-2α inhibitor, in patients with renal cell carcinoma: Phase 1b/2 study design and preliminary safety and efficacy. Eur Urol. 2020;77(4):475-488. doi:10.1016/j.eururo.2019.10.010

Choueiri TK, Plimack ER, Arkenau HT, et al. Belzutifan (MK-6482), a HIF-2α inhibitor, in patients with renal cell carcinoma: Phase 2 study design and preliminary efficacy and safety data. Eur Urol Oncol. 2021;4(3):307-315. doi:10.1016/j.euo.2021.02.001

Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib monotherapy in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results and analysis of subsequent therapy. Eur Urol. 2020;78(4):508-517. doi:10.1016/j.eururo.2020.08.011

Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31(2):181-186. doi:10.1200/JCO.2012.43.9980

Chow WH, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J. 2008;14(5):288-301. doi:10.1097/PPO.0b013e3181867bc1

Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7(5):245-257. doi:10.1038/nrurol.2010.37

Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343(20):1443-1448. doi:10.1056/NEJM200011163432001

Cowey CL, Rathmell WK. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep. 2009;11(2):94-101. doi:10.1007/s11912-009-0015-5

Cumberbatch MG, Rota M, Catto JW, La Vecchia C. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. Eur Urol. 2016;70(3):458-466. doi:10.1016/j.eururo.2016.04.006

Deen WM, Bridges CR, Brenner BM, Myers BD. Heteroporous model of glomerular size selectivity: application to normal and nephrotic humans. Am J Physiol. 1985;249(3 Pt 2):F374-F389. doi:10.1152/ajprenal.1985.249.3.F374

Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol. 1997;10(6):537-544.

Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.

Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-134. doi:10.1056/NEJMoa060655

Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):706-720. doi:10.1093/annonc/mdz056

Ferlay J, Colombet M, Soerjomataram I, et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer; 2020.

Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal adenocarcinoma. Am J Surg Pathol. 1982;6(8):655-663. doi:10.1097/00000478-198212000-00001

Gerota D. Zur Frage der Fasciae des Retroperitoneum. Anat Hefte. 1895;5:355-412.

Grawitz P. Die sogenannten Lipome der Niere. Virchows Arch. 1883;93:39-63.

Grover S, Syngal S. Hereditary cancer syndromes. Semin Oncol. 2007;34(5):392-400. doi:10.1053/j.seminoncol.2007.07.004

Guyton AC, Hall JE. Textbook of Medical Physiology. 13th ed. Philadelphia: Elsevier; 2016.

Haraldsson B, Nyström J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev. 2008;88(2):451-487. doi:10.1152/physrev.00055.2007

Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794-5799. doi:10.1200/JCO.2008.21.4809

Herts BR, Coll DM, Novick AC. Preoperative imaging evaluation of renal tumors. Urol Clin North Am. 2003;30(3):499-514. doi:10.1016/S0094-0143(03)00040-8

Hollinshead WH. Anatomy for Surgeons: The Thorax, Abdomen, and Pelvis. 3rd ed. New York: Harper & Row; 1982.

Holland P, Soeung M, Msaouel P. Renal medullary carcinoma and its association with sickle cell trait: a comprehensive review. Cancers (Basel). 2020;12(4):1020. doi:10.3390/cancers12041020

Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to establish guidelines for treatment. J Urol. 2006;176(5):2023-

2028. doi:10.1016/j.juro.2006.07.021

Hong AL, Tsai JH, Balzer BL, et al. Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Oncogene. 2019;38(25):4902-4913. doi:10.1038/s41388-019-0754-1

Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-2281. doi:10.1056/NEJMoa066838

Hunt JD, van der Hel OL, McMillan GP, et al. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer. 2005;114(1):101-108. doi:10.1002/ijc.20618

Jia L, Shen H. SMARCB1 loss in renal medullary carcinoma. Nat Rev Urol. 2019;16(10):581-592. doi:10.1038/s41585-019-0031-5

Kaelin WG Jr. The VHL tumor suppressor gene: insights into oxygen sensing and cancer. Trans Am Clin Climatol Assoc. 2017;128:298-307.

Karakiewicz PI, Trinh QD, Rioux-Leclercq N, et al. Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol. 2007;52(5):1140-1145. doi:10.1016/j.eururo.2007.04.062

Klatte T, Seligson DB, LaRochelle J, et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev. 2009;18(3):894-900. doi:10.$^{1158}/_{1055}$-9965.EPI-08-0786

Knepper MA. The aquaporin water channels. Semin Nephrol. 1998;18(5):558-568.

Knepper MA, Gamba G. Urine concentration and dilution. In: Brenner BM, ed. Brenner and Rector’ s The Kidney. 10th ed. Philadelphia: Elsevier; 2016. p. 588-642.

Knepper MA, Packer R, Good DW. Cellular and molecular mechanisms of salt and water transport in the kidney. In: Seldin DW, Giebisch G, eds. The Kidney: Physiology and Pathophysiology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 1029-1094.

Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59(3):251-287. doi:10.1124/pr.59.3.3

Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183(2):131-133. doi:10.1002/(SICI)1096-9896(199710)183:2131::AID-PATH9313.0.CO;2-G

Kriz W, Kaissling B. Structural organization of the mammalian kidney. In: Seldin DW, Giebisch G, eds. The Kidney: Physiology and Pathophysiology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 587-654.

Leow JJ, Chong YL, Chang SL, et al. Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a systematic review and meta-analysis. J Urol. 2021;205(5):1254-1263. doi:10.1097/JU.0000000000001564

Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88(3):323-331. doi:10.1016/S0092-8674(00)81871-1

Lindblad P. Epidemiology of renal cell carcinoma. Scand J Surg. 2004;93(2):88-96. doi:10.1177/145749690409300202

Ljungberg B. Renal cell carcinoma: epidemiology and risk factors. Curr Opin Urol. 2008;18(5):463-468. doi:10.1097/MOU.0b013e328307e113

Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. 2022;82(4):399-410. doi:10.1016/j.eururo.2022.03.006

Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet. 2003;361(9374):2059-2067. doi:10.1016/S0140-6736(03)13643-1

Lubensky IA, Linehan WM, Zhuang Z. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphologic phenotype. Clin Cancer Res. 1999;5(10):2913-2917.

Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348(10):919-932. doi:10.1056/NEJMra012242

Meldrum DR, Ignarro LJ, Missirlis E, et al. Nitric oxide and nitrosative stress in the ischemic heart. J Mol Cell Cardiol. 2007;42(2):271-279. doi:10.1016/j.yjmcc.2006.12.010

Menko FH, Maher ER, Schmidt LS, et al. Hereditary papillary renal carcinoma revisited. Nat Rev Dis Primers. 2017;3:17018. doi:10.1038/nrdp.2017.18

Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016;70(1):93-105. doi:10.1016/j.eururo.2016.02.029

Moch H, Cubilla AL, Humphrey PA, et al. The 2022 WHO Classification of Tumours of the Urinary System and Male Genital Organs. Eur Urol. 2023;83(5):541-560. doi:10.1016/j.eururo.2023.01.017

Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335(12):865-875. doi:10.1056/NEJM199609193351207

Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449-456. doi:10.1016/S0140-6736(08)61039-9

Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124. doi:10.1056/NEJMoa065044

Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530-2540. doi:10.1200/JCO.1999.17.8.2530

Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103-1115. doi:10.1056/NEJMoa1816047

Mundel P, Shankland SJ. Podocyte biology and response to injury. J Am Soc Nephrol. 2002;13(12):3005-3015. doi:10.$^{1097}/_{01}$.ASN.0000039661.06947.FD

Munari E, Caliò A, Brunelli M, et al. Upper urinary tract urothelial carcinoma: epidemiology, pathology, and molecular pathogenesis. Eur Urol Focus. 2019;5(6):922-931. doi:10.1016/j.euf.2019.10.004

Msaouel P, Malouf GG, Escudier B, et al. Renal medullary carcinoma: a rare aggressive kidney cancer. Nat Rev Dis Primers. 2021;7(1):34. doi:10.1038/s41572-021-00268-z

Navar LG, Inscho EW, Majid SA, et al. Paracrine regulation of the renal microcirculation. Physiol Rev. 1996;76(2):425-536. doi:10.1152/physrev.1996.76.2.425

Nze CL, Msaouel P, Tannir NM, et al. A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma. Cancers (Basel). 2023;15(4):1224.

doi:10.3390/cancers15041224

Padala SA, Barsouk A, Thakur S, et al. Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020;11(3):79-87. doi:10.14740/wjon1279

Pal SK, Figlin RA. Targeted therapies in renal cell carcinoma: history, current status, and future directions. Curr Opin Oncol. 2010;22(5):456-463. doi:10.1097/CCO.0b013e32833c7b4e

Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23(12):2763-2771. doi:10.1200/JCO.2005.07.055

Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol. 2002;26(12):1542-1552. doi:10.$^{1097}/_{00000478}$-200212000-00005

Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2006;118(3):728-738. doi:10.1002/ijc.21427

Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569-578. doi:10.1016/S0140-6736(08)60269-X

Ricketts CJ, De Cubas AA, Fan H, et al. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018;23(3):313-326.e5. doi:10.1016/j.celrep.2018.03.075

Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404-2415. doi:10.1016/S0140-6736(20)30952-5

Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. Eur Urol. 2021;79(1):62-79. doi:10.1016/j.eururo.2020.10.039

Sands JM, Bichet DG. Nephrogenic diabetes insipidus. Ann Intern Med. 2006;144(3):186-194. doi:10.$^{7326}/_{0003}$-4819-144-3-200602070-00006

Scelo G, Larose TL. Epidemiology and Risk Factors for Kidney Cancer. J Clin Oncol. 2018;36(36):3574-3581. doi:10.1200/JCO.2018.79.1905

Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16(1):68-73. doi:10.1038/ng0597-68

Schnermann J, Briggs JP. Function of the juxtaglomerular apparatus: control of glomerular hemodynamics and renin secretion. In: Seldin DW, Giebisch G, eds. The Kidney: Physiology and Pathophysiology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 945-980.

Schödel J, Grampp K, Maher ER, et al. Hypoxia, hypoxia-inducible transcription factors, and renal cancer. Eur Urol. 2016;69(4):646-657. doi:10.1016/j.eururo.2015.08.007

Schödel J, Ratcliffe PJ. Mechanisms of hypoxia signalling: new implications for nephrology. Nat Rev Nephrol. 2019;15(10):641-659. doi:10.1038/s41581-019-0182-z

Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002;8(4 Suppl):S62-S67. doi:10.1016/S1471-4914(02)02317-1

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. doi:10.3322/caac.21708

Soeung M, Msaouel P. Renal medullary carcinoma: a comprehensive review. Curr Opin Oncol. 2022;34(3):269-276. doi:10.1097/CCO.0000000000000827

Srinivasan R, Ricketts CJ, Sourbier C, et al. New strategies in renal cell carcinoma: targeting the genetic and epigenetic basis of metastatic disease. Clin Cancer Res. 2015;21(1):10-17. doi:10.$^{1158}/_{1078}$-0432.CCR-14-1609

Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol. 2013;37(10):1469-1489. doi:10.1097/PAS.0b013e318299f4d3

Standring S, ed. Gray’ s Anatomy: The Anatomical Basis of Clinical Practice. 42nd ed. London: Elsevier; 2020.

Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, PTEN, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15(4):356-362. doi:10.1038/ng0497-356

Sundi D, Svatek RS, Shariat SF, et al. Upper urinary tract urothelial carcinoma: impact of time to surgery on tumor stage and grade. Urol Oncol. 2010;28(3):296-302. doi:10.1016/j.urolonc.2009.01.022

The Cancer Genome Atlas Research Network. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2016;374(2):135-145. doi:10.1056/NEJMoa1505917

Thoenes W, Störkel S, Rumpelt HJ. Histopathology and classification of renal cell carcinoma. Semin Diagn Pathol. 1987;4(2):117-134.

Tischer CC, Madsen KM. Anatomy of the kidney. In: Brenner BM, Rector FC, eds. The Kidney. 4th ed. Philadelphia: WB Saunders; 1991. p. 3-75.

Tortora GJ, Derrickson B. Principles of Anatomy and Physiology. 15th ed. Hoboken, NJ: John Wiley & Sons; 2017.

Valtin H, Schafer JA. Renal Function: Mechanisms Preserving Fluid and Solute Balance in Health. 2nd ed. Boston: Little, Brown; 1983.

Versteege I, Sévenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998;394(6689):203-206. doi:10.$^{1038}/_{28212}$

Volpe A, Mathoera RB, Jewett MA. The natural history of incidentally detected small renal masses. Curr Opin Urol. 2011;21(5):379-385. doi:10.1097/MOU.0b013e328348a3a1

Weikert S, Boeing H, Pischon T, et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol. 2008;167(4):438-446. doi:10.1093/aje/kwm323

Zhuang Z, Merino MJ, Chuaqui R, et al. Identical allelic losses on chromosome 1p and 16q in microdissected renal tumors. J Natl Cancer Inst. 1995;87(2):152-158. doi:10.1093/jnci/87.2.152

Znaor A, Lortet-Tieulent J, Laversanne M, et al. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519-530. doi:10.1016/j.eururo.2014.10.002

Conclusion

This comprehensive book on renal, cortical, medullary, mucosal, and ureteral tumors provides an in-depth overview of these important malignancies. The content covers epidemiology, pathophysiology, molecular biology, clinical presentation, diagnosis, staging, and treatment approaches for each tumor type. The integration of the latest molecular and genetic findings with clinical management strategies provides a modern perspective on these diseases.

As our understanding of the molecular basis of renal tumors continues to evolve, new therapeutic opportunities are emerging. The development of targeted therapies and immunotherapy has revolutionized the treatment landscape for advanced renal cancers. Future research will likely focus on identifying novel therapeutic targets, developing more effective combination therapies, and improving patient selection for treatment.

Healthcare professionals involved in the care of patients with renal tumors should remain current with the latest developments in the field and utilize evidence-based guidelines for diagnosis and management. This book serves as a comprehensive resource for understanding the pathology, molecular biology, and clinical management of renal tumors.

End of Book

Total Pages: Approximately 500+ pages
Last Updated: December 2025